6TH ANNUAL MEETING
OF THE INTERNATIONAL CYTOKINE
& INTERFERON SOCIETY

27-30 October 2018
Westin Boston Waterfront, Boston, USA

FINAL PROGRAM
At Janssen, we like to dream big. And our hope for immune and inflammatory diseases is no exception.

Through science and collaboration, we look to transform how diseases like rheumatoid arthritis, Crohn’s disease and plaque psoriasis are treated today—and prevented tomorrow.

We dream of a future free of the pain and challenges for the approximately one in 10 people worldwide living with these diseases. We are relentless in our pursuit to advance science and deliver breakthrough medicines to make a difference in people’s lives.

But bringing forward new solutions isn’t enough. We want to shorten the journey from diagnosis to treatment. And through our education and access programs, we’re here to help forge that path.

We are Janssen. We collaborate with the world for the health of everyone in it.

Learn more at www.janssen.com
# TABLE OF CONTENTS

Welcome Message ....................................................................................................................................................4
Committee Members ................................................................................................................................................4
General Information ..............................................................................................................................................6-7
Networking Events ....................................................................................................................................................8
Program Overview ............................................................................................................................................ 11-12

## Scientific Program

- **Saturday, 27 October 2018** ........................................................................................................................13
- **Sunday, 28 October 2018** ........................................................................................................................14-16
- **Monday, 29 October 2018** .........................................................................................................................17-19
- **Tuesday, 30 October 2018** .........................................................................................................................19-22

Poster Sessions ..................................................................................................................................................23-39
Award Winners .................................................................................................................................................40-41
Company Profiles ..............................................................................................................................................42-47
Layout of Venue & Exhibition Area ..........................................................................................................................49

Acknowledgements ................................................................................................................................................50
WELCOME MESSAGE

Dear Colleagues,

We would like to welcome you to the 6th Annual Meeting of the International Cytokine & Interferon Society (ICIS) in Boston.

The ICIS Annual Meetings have typically attracted more than 500 registrants and have a distinguished history of presenting cutting edge research from internationally-recognized scientists. The objective of the meeting is to promote interactions between scientists performing basic and translational studies on the molecular mechanisms of cytokine and interferon function, signal transduction, and gene expression in the context of health and disease. Working with our scientific advisory committee, a diverse scientific program has been prepared that is composed of outstanding trainees, junior and senior scientists that cover the breadth of cytokine biology.

The ICIS annual meeting has become the world’s most important annual conference on basic, clinical and translational research on cytokines and their roles in host defense, inflammation, tissue repair and cancer.

The dissemination of knowledge that takes place at such meetings and the interactions and collaborations that are established are essential for future advances in biomedical research.

We believe this will be a fantastic meeting in a great city, with many networking opportunities and hope that you make the most of the opportunities it provides.

We wish you a successful meeting!

Christopher Hunter
Katherine Fitzgerald
Anne O’Garra

COMMITTEE MEMBERS

Meeting Chairs
Christopher Hunter (USA)
Katherine Fitzgerald (USA)
Anne O’Garra (UK)

Scientific Advisory Board
Judith Allen (UK)
Clare Bryant (UK)
Richard A. Flavell (USA)
John Harris (USA)
Brendan J. Jenkins (AU)
Jonathan C. Kagan (USA)
Carolina Lopez (USA)
Nancy Reich (USA)
Ganes Sen (USA)
Tadatsugu Taniguchi (JP)
Hiroki Yoshida (JP)
Elina Zuniga (USA)
Unsurpassed Expertise in IFN ELISA and Reagent Manufacturing

Highly Sensitive Type I IFN ELISA Kits For Human and Mouse

NAb to Human IFNAR2 Universal Type I IFN ISG15 NAb & More...

PBL Assay Science, your trusted source for interferon ELISAs, proteins, antibodies, and assay services is proud to be a sponsor for the 6th Annual Meeting of the International Cytokine & Interferon Society (ICIS)! As PBL's product lines expand to include additional cytokine targets, new technologies, and expanded assay services, our scope is broadening. We invite you to visit with our scientists (Booth 4/5) at the ICIS exhibition to see how we can address your challenging assay problems.
GENERAL INFORMATION

MEETING VENUE AND LOCATION
The Westin Boston Waterfront
425 Summer Street
Boston, MA, 02210
Phone: +1 (617) 532-4600

MEETING ORGANIZER
MCI Suisse SA has been selected by ICIS as the official meeting organizer to process registrations, abstract management, exhibition and sponsorship. All correspondence should be sent to:
Cytokines 2018
c/o MCI Suisse SA
9 Rue de Pré-Bouvier
1242 Satigny, Geneva, Switzerland
General contact: cytokines@mci-group.com

ICIS HEADQUARTERS
Joan Oefner, Managing Director
International Cytokine & Interferon Society (ICIS)
297 Kinderkamack Road, Suite 348
Oradell, NJ 07649 USA
Tel. 1-800-947-1960 / +49-171-1049-181
Fax: 1-201-322-1818
www.cytokinesociety.org
E-mail: joefner@cytokinesociety.org

MEETING DOCUMENTS AND BADGES
Meeting documents should be collected on-site at the registration desk at the Westin Boston Waterfront - Grand Ballroom Foyer - Ground Level. Name badges must be worn visibly all times during the meeting and in the exhibition area.

MOBILE APPLICATION
Get all information you need at your fingertips with the Cytokines 2018 Mobile Application. It is available for free on iOS and Android.

CELLULAR PHONES AND PAGERS
As a courtesy to all meeting attendees and speakers, cellular phones, pagers and other electronic devices must be operated in silent or vibration mode during sessions. No cellular phone conversations are permitted during sessions. Picture taking, filming or recording of the sessions is forbidden.

CERTIFICATE OF ATTENDANCE
A certificate of attendance will be sent by email after the meeting to all duly registered participants who attended the meeting.

FOOD AND BEVERAGE
Complimentary coffee, tea and snacks is served in the exhibition during official coffee breaks. Lunch will be provided to the attendees of the lunchtime sessions only. For other delegates, there are several restaurants within walking distance of the Westin Boston Waterfront building. Check out restaurants in the surroundings by scanning the QR code.

INTERNET
Free wireless internet access is available in the meeting spaces. WiFi Name: Westin Conference Password: Cytokines2018

OFFICIAL LANGUAGE
The official meeting language is English. No simultaneous interpretation will be available.

SMOKING POLICY
The meeting venue is entirely non-smoking.

SURVEY/MEETING EVALUATION
We would be grateful if you can take a few minutes to answer an online survey that will be sent to you shortly after the meeting. Your valuable feedback will help us to improve the organization and quality of future Cytokines meetings.

REGISTRATION DESK OPENING HOURS
<table>
<thead>
<tr>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, 27 October</td>
<td>14:00 - 20:30</td>
</tr>
<tr>
<td>Sunday, 28 October</td>
<td>07:30 - 19:00</td>
</tr>
<tr>
<td>Monday, 29 October</td>
<td>08:00 - 19:00</td>
</tr>
<tr>
<td>Tuesday, 30 October</td>
<td>08:00 - 18:00</td>
</tr>
</tbody>
</table>

EXHIBITION OPENING HOURS
<table>
<thead>
<tr>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, 27 October</td>
<td>14:00 - 20:30</td>
</tr>
<tr>
<td>Sunday, 28 October</td>
<td>10:00 - 16:30</td>
</tr>
<tr>
<td>Monday, 29 October</td>
<td>10:00 - 16:30</td>
</tr>
<tr>
<td>Tuesday, 30 October</td>
<td>10:00 - 16:00</td>
</tr>
</tbody>
</table>

TRAVEL INSURANCE
It is recommended that participants obtain adequate cover for travel, health and accident insurance before they depart from their countries. Cytokines 2018 and MCI Suisse S.A. as organizers cannot accept responsibility for personal injuries, or loss of, or damage to, private property belonging to the delegates and accompanying persons.

WEBSITE
www.boston.cytokinesociety.org
Antibodies Recognize Antigens...

How will you get **recognized** for your immunology research?

*Science Immunology* publishes original, peer-reviewed, science-based research articles that report critical advances in all areas of immunological research, including important new tools and techniques.

For more information: [ScienceImmunology.org](http://ScienceImmunology.org)
Saturday, 27 October  
19:30-20:30  
Welcome Mixer  
Grand Ballroom Foyer  
Join your colleagues, meet new friends to celebrate a great start of the Cytokines 2018 meeting!

Saturday, 27 October  
20:30-22:30  
Poster session 1 & Light Reception  
Pavilion & Grand Ballroom Foyer  
Do not miss poster presentations of the selected abstracts.

Sunday, 28 October  
20:30-22:30  
Poster session 2 & Light Reception  
Pavilion & Grand Ballroom Foyer  
Join us for the 2nd round of poster presentations.

Monday, 29 October  
19:00-23:00  
Conference Dinner - Spirit of Boston Cruise  
Cast off with new friends and long-time colleagues aboard the Spirit of Boston for a dinner cruise with a great view of Boston harbor on Monday night, reserved exclusively for Cytokines 2018!  
Enjoy breathtaking views, unlimited beverages, a delicious buffet dinner, music and dancing. The Metabollix live band led by Luke O’Neill will be our special guests for this memorable evening.  
Please do not forget your Boston Spirit Ticket.  
Tickets must be purchased in advance and are on a space available basis. Further information at the registration counter.

Schedule of the evening:
19:00-20:00  Boarding at WTC Harbor, Beer & Wine Open Bar Reception, Music at Dockside  
20:00-22:00  Cruise, Dinner, Beer & Wine Open Bar, Live Music  
22:00-23:00  Dockside at the WTC Harbor, Beer & Wine Open Bar, Music at Dockside  
(disembarking from the ship is possible beginning at 22:00)

SAVE THE DATE

7th Annual Meeting of the International Cytokine & Interferon Society  
20 - 23 October 2019  
Hofburg Palace  
Vienna, Austria

Chair of the Meeting  
George Schett  
University of Erlangen-Nuremberg  
Institute for Clinical Immunology  
Germany

Cytokines 2019  
International Cytokine & Interferon Society ICIS
WHY SUBMIT TO JEM?

AN EDITORIAL PROCESS GUIDED BY YOUR COMMUNITY

At Journal of Experimental Medicine, all editorial decisions on research manuscripts are made through collaborative consultation between professional scientific editors and the academic editorial board.

Submission or transfer

Academic and scientific editors review

If appropriate, sent to peer review

Academic and scientific editors review comments

Informed decisions sent to authors

Revised manuscript submission and review

Academic and scientific editors review

96% of invited revisions accepted*

Published online 1-2 days after author proofs returned

Circulated via alerts and social media to readers around the world

96% OF INVITED REVISIONS ARE ACCEPTED.

INITIAL DECISION IN 5 DAYS

TIME IN PEER REVIEW 35 DAYS

*Median 2017

Format Neutral
You may submit your papers in ANY format.

Transfer Policy
We welcome submissions that include reviewer comments from another journal. You may also request manuscript transfer between Rockefeller University Press journals, and we can confidentially send reviewer reports and identities to another journal beyond JEM.

Fair and Fast
We limit rounds of revision, and we strive to provide clear, detailed decisions that illustrate what is expected in the revisions. Articles appear online one to two days after author proofs are returned.

Open Access Options
Our options include immediate Open Access (CC-BY) and open access six months after publication (CC-BY-NC-SA).
At Five Prime Therapeutics, our success comes from our ability to take an unbiased approach to screening for potential treatments using our powerful platform. Our team questions the fundamental roles that extracellular signaling proteins play in disease processes. We believe that the new pathways and targets revealed by these insights will allow us to develop new therapeutics for diseases that remain significant causes of suffering and death.

Our industry-leading, IND engine has helped us identify novel pathways and targets in immuno-oncology and other areas to build a growing clinical pipeline.

Our robust pipeline is made up of first-in-class agents or agents that we believe are meaningfully differentiated from others in the class.
### PROGRAM OVERVIEW

#### Saturday, 27 October 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Event Details</th>
</tr>
</thead>
</table>
| 17:00 – 19:30 | GRAND BALLROOM AB    | Opening Ceremony  
President’s Lecture  
Awards Ceremony  
Keynote Lecture |
| 19:30 – 20:30 | GRAND BALLROOM FOYER | Welcome Mixer                                                                 |
| 20:30 – 22:30 | PAVILION & GRAND BALLROOM FOYER | POSTER SESSION I with Wine, Beer and Snacks |

#### Sunday, 28 October 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Event Details</th>
</tr>
</thead>
</table>
| 08:30 – 10:30 | GRAND BALLROOM AB    | Plenary Session 1  
Immunoregulation |
| 10:30 – 11:00 | GRAND BALLROOM FOYER | Coffee Break & Visit of the Exhibition |
| 11:00 – 12:35 | GRAND BALLROOM A     | Symposium 1  
Innate Sensing & Signaling |
| 11:00 – 12:35 | GRAND BALLROOM B     | Symposium 2  
Antiviral Responses |
| 12:35 – 14:00 | GRAND BALLROOM A     | Lunch break - On own |
| 12:45 – 13:45 | GRAND BALLROOM B     | LUNCH SYMPOSIUM  
TARGETED CYTOKINE THERAPY |
| 14:00 – 16:00 | GRAND BALLROOM A     | Symposium 3  
Inflammasomes, Interferons and Beyond |
| 14:00 – 16:00 | GRAND BALLROOM B     | Symposium 4  
Infection and Inflammation in the Lung |
| 16:00 – 16:30 | GRAND BALLROOM FOYER | Coffee Break & Visit of the Exhibition |
| 16:30 – 18:30 | GRAND BALLROOM A     | Symposium 5  
Cytokines in Neuronal Inflammation |
| 16:30 – 18:30 | GRAND BALLROOM B     | Symposium 6  
Intestinal Homeostasis |
| 18:30 – 20:30 | GRAND BALLROOM A     | Dinner break - On own |
| 20:30 – 22:30 | PAVILION & GRAND BALLROOM FOYER | POSTER SESSION II with Wine, Beer and Snacks |
### Monday, 29 October 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Grand Ballroom A</th>
<th>Grand Ballroom B</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:45 – 08:30</td>
<td>ICIS Members Business Meeting / Milstein Travel Awards</td>
<td>Plenary Session 2 Advances in Pathogenic Th17 Axis of Evil</td>
</tr>
<tr>
<td>08:30 – 10:35</td>
<td></td>
<td>Advances in Pathogenic Th17 Axis of Evil</td>
</tr>
<tr>
<td>10:35 – 11:00</td>
<td></td>
<td>Coffee Break &amp; Visit of the Exhibition</td>
</tr>
<tr>
<td>11:00 – 12:35</td>
<td>Symposium 7 Type II Immunity</td>
<td>Symposium 8 Innate Cytokines and Cancer</td>
</tr>
<tr>
<td>12:35 – 14:00</td>
<td>Lunch break - On own</td>
<td></td>
</tr>
<tr>
<td>12:45 – 13:45</td>
<td>Biotech/Venture Capital Panel Discussion</td>
<td>Meet the Editors</td>
</tr>
<tr>
<td>14:00 – 16:00</td>
<td>Symposium 9 Immunoregulation II</td>
<td>Symposium 10 Type III and other IFNs</td>
</tr>
<tr>
<td>16:00 – 16:30</td>
<td>Coffee Break &amp; Visit of the Exhibition</td>
<td></td>
</tr>
<tr>
<td>16:30 – 18:10</td>
<td>Symposium 11 Cytokines and Cancer II</td>
<td>Symposium 12 Type I IFNs in Disease</td>
</tr>
<tr>
<td>19:00 – 23:00</td>
<td>CONFERENCE DINNER – SPIRIT OF BOSTON CRUISE</td>
<td></td>
</tr>
</tbody>
</table>

### Tuesday, 30 October 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Grand Ballroom A</th>
<th>Grand Ballroom B</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 – 10:30</td>
<td>Symposium 13 Philip I. Marcus Symposium</td>
<td>Symposium 14 Dermal Responses, Cytokines</td>
</tr>
<tr>
<td>10:30 – 11:00</td>
<td>Coffee Break &amp; Visit of the Exhibition</td>
<td></td>
</tr>
<tr>
<td>11:00 – 12:35</td>
<td>Symposium 15 Inflammasome and IL1 Family members II</td>
<td>Symposium 16 Infection and Immunity</td>
</tr>
<tr>
<td>12:35 – 14:00</td>
<td>Lunch break - On own</td>
<td></td>
</tr>
<tr>
<td>12:55 – 13:50</td>
<td>Trainee workshop A: CANCER</td>
<td>Trainee workshop B: INNATE IMMUNITY</td>
</tr>
<tr>
<td>14:00 – 15:40</td>
<td>Symposium 17 T cell regulation in Cancer</td>
<td>Symposium 18 Cytokines: Beyond the Age of Discovery</td>
</tr>
<tr>
<td>15:40 – 15:55</td>
<td>Coffee Break &amp; Visit of the Exhibition</td>
<td></td>
</tr>
<tr>
<td>15:55 – 17:25</td>
<td>Plenary Session 3 Tissue specific responses - Gut, Lung and Lymph nodes</td>
<td></td>
</tr>
<tr>
<td>17:25 – 17:30</td>
<td>CONFERENCE WRAP UP – Invitation to Cytokines 2019 in Vienna</td>
<td></td>
</tr>
</tbody>
</table>
Saturday, 27 October 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:00 – 19:25</td>
<td>OPENING CEREMONY</td>
<td>Grand Ballroom AB</td>
</tr>
<tr>
<td>17:00 – 17:05</td>
<td>Welcome and Opening Remarks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chris Hunter (for the organizers)</td>
<td></td>
</tr>
<tr>
<td>17:05 – 18:45</td>
<td>Awards Ceremony – Presentations and Milstein Award Lectures</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: Nancy Reich</td>
<td></td>
</tr>
<tr>
<td>17:05 – 17:15</td>
<td>Milstein Awardees Introduction</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nancy Reich</td>
<td></td>
</tr>
<tr>
<td>17:15 – 17:50</td>
<td>MILSTEIN Awardee LECTURE I: Krebs Cycle drives signals for inflammation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Luke O’Neill (Trinity College Dublin, Ireland)</td>
<td></td>
</tr>
<tr>
<td>17:50 – 18:25</td>
<td>MILSTEIN Awardee LECTURE II: Regulation of inflammasome activation and cell death</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thirumala Kanneganti (St. Judes, USA)</td>
<td></td>
</tr>
<tr>
<td>18:25 – 18:45</td>
<td>Awardees Ceremony</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Bryan Williams and Kate Fitzgerald</td>
<td></td>
</tr>
<tr>
<td>18:45 – 19:25</td>
<td>ICIS Honorary Lifetime Member Awardee:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Robert Fleischmann (Central Michigan University College of Medicine, USA)</td>
<td></td>
</tr>
<tr>
<td>19:30 – 20:30</td>
<td>WELCOME MIXER</td>
<td>Grand Ballroom Foyer</td>
</tr>
<tr>
<td></td>
<td>Sponsored by Pfizer</td>
<td></td>
</tr>
<tr>
<td>20:30 – 22:30</td>
<td>POSTER SESSION I with Wine, Beer and Snacks</td>
<td>Pavilion &amp; Grand Ballroom Foyer</td>
</tr>
</tbody>
</table>

Pfizer
### Sunday, 28 October 2018

#### 08:30 – 10:30  
**PLENARY 1: IMMUNOREGULATION**

_Sponsored by Pfizer*

**Chairs:** Anne O’Garra and Maria Grazia Roncarolo

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 – 08:55</td>
<td>Transcriptional regulation of IL-10 versus proinflammatory cytokines and consequences for the immune response - Anne O’Garra (Francis Crick Institute, UK)</td>
</tr>
<tr>
<td>08:55 – 09:20</td>
<td>The development and function of IL-10 producing Type 1 regulatory T cells - Maria Grazia Roncarolo (Stanford, USA)</td>
</tr>
<tr>
<td>09:20 – 09:45</td>
<td>Cytokine cues in regulatory T cell differentiation and function - Alexander Rudensky (Memorial Sloan Kettering, USA)</td>
</tr>
<tr>
<td>09:45 – 10:00</td>
<td>O01 - Treatment with heterodimeric IL-15 shapes the cytokine and chemokine milieu of the tumor, promoting tumor infiltration by cytotoxic lymphocytes: a general method for lymphocyte entry in tumors - Cristina Bergamaschi (NIH, MD)</td>
</tr>
<tr>
<td>10:00 – 10:15</td>
<td>O02 - Regulation of novel pattern recognition receptor signaling and IFN induction by unanchored K48-linked polyubiquitin chains - Ricardo Rajsbaum (UTMB, TX)</td>
</tr>
<tr>
<td>10:15 – 10:30</td>
<td>O03 - Delineation of the inflammatory pathway behind proteasome-associated autoinflammatory syndrome - Sophia Davidson (WEHI, Australia)</td>
</tr>
<tr>
<td>10:30 – 11:00</td>
<td><strong>COFFEE BREAK &amp; VISIT OF THE EXHIBITION</strong></td>
</tr>
</tbody>
</table>

#### 10:30 – 11:00  
**COFFEE BREAK & VISIT OF THE EXHIBITION**

#### 11:00 – 12:35  
**SYMPOSIUM 1: INNATE SENSING AND SIGNALING**

_Sponsored by Takeda*

**Chairs:** Kate Fitzgerald and James Chen

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 11:25</td>
<td>Cytokine gene regulation - Kate Fitzgerald (UMass Medical School, USA)</td>
</tr>
<tr>
<td>11:25 – 11:50</td>
<td>A novel receptor involved in the recognition of DAMPs and cell death - Ken Rock, (UMass Medical School, USA)</td>
</tr>
<tr>
<td>11:50 – 12:15</td>
<td>DNA sensing by cGAS - James Chen (UTSW, USA)</td>
</tr>
<tr>
<td>12:15 – 12:25</td>
<td>O04 - Di- and trimeric biological switches made of nanobody-cytokine receptor fusion proteins simulate natural signal transduction - Erika Engelowski (Heinrich-Heine-University, Germany)</td>
</tr>
<tr>
<td>12:25 – 12:35</td>
<td>O05 - A metabolite-triggered tuft cell-ilk2 circuit drives small intestinal remodelling - Christoph Schneider (UCSF, CA)</td>
</tr>
</tbody>
</table>

#### 11:00 – 12:35  
**SYMPOSIUM 2: ANTIVIRAL RESPONSES**

**Chairs:** Carolina Lopez and Elina Zuniga

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 11:25</td>
<td>Type I interferon exhaustion - Elina Zuniga (UCSD, USA)</td>
</tr>
<tr>
<td>11:25 – 11:50</td>
<td>Defective (interfering) viral genomes re-explored: Impact on antiviral immunity and virus persistence - Carolina Lopez (UPenn, USA)</td>
</tr>
<tr>
<td>11:50 – 12:15</td>
<td>The good, the bad, and the ugly consequences of CD8 T cell memory to RSV - Steve Varga (University of Iowa, USA)</td>
</tr>
</tbody>
</table>

* Sponsored sessions are organized by the scientific committee and the industry sponsor provides support without influence on topic, content or speakers.
12:15 – 12:25  O06 - Type I interferon signaling attenuates regulatory T cell function in viral infection and in the tumor microenvironment - Arunakumar Gangaplara (NIAID, USA)

12:25 – 12:35  O07 - Gap-junction dependent trans-activation of human monocytes by CGAMP - Genevieve Pepin (Hudson Institute, Australia)

**12:35 – 14:00 LUNCH BREAK - ON OWN**

**12:45 – 13:45 LUNCH SYMPOSIUM: TARGETED CYTOKINES THERAPY**  
**Grand Ballroom B**

*Chair: Simon Jones*

12:45-13:15  The anti-TNF success story and the new challenges ahead - Jochen Salfeld (Abbvie, USA)

13:15-13:45  Dupilumab confirms the role of IL-4 and IL-13 as central drivers of type 2 immunity in human disease - Jamie Orengo (Regeneron, USA)

*Lunch provided to session attendees only*

**14:00 – 16:00 SYMPOSIUM 3: INFLAMMASOMES, INTERFERONS AND BEYOND**  
**Grand Ballroom A**

*Sponsored by Sanofi*

*Sanofi  Chairs: Clare Bryant and Igor Brodsky*

14:00 – 14:25  Pathogenic effects of IFIT2 and IFN-β during fatal systemic C.albicans infection - Nancy Reich (Stony Brook University, NY, USA)

14:25 – 14:50  It's in the CARDs - understanding the distinction between pyroptosis and hyper activation - Igor Brodsky (UPenn, USA)

14:50 – 15:15  Following the speck: pattern recognition receptors in bacterial infections - Clare Bryant (Cambridge, UK)

15:15 – 15:40  Pyroptosis: from innate immunity to cancer - Feng Shao (Beijing, China)

15:40 – 16:00  O08 - GSDMD is critical for autoinflammatory pathology in a mouse model of familial Mediterranean fever - Apurva Kanneganti (Harvard College, USA)

**14:00 – 16:00 SYMPOSIUM 4: INFECTION AND INFLAMMATION IN THE LUNG**  
**Grand Ballroom B**

*Sponsored by Regeneron*

*Regeneron  Chairs: Andrew McKenzie and Clare Lloyd*

14:00 – 14:25  Immune regulation in the allergic lung - Clare Lloyd (Imperial College London, UK)

14:25 – 14:50  IL-33 and ILCs - John Silver (Medimmune, MD, USA)

14:50 – 15:15  IL-33 and ILC2 in the regulation of adaptive immunity and metabolism - Andrew McKenzie (MRC, UK)

15:15 – 15:40  Multifaceted roles of type I interferons in respiratory infections - Andreas Wack (Crick Institute, UK)

15:40 – 16:00  O10 - Modulation of interleukin-22 alleviate respiratory viral infection by promoting epithelial intrinsic type I interferon response - Ran Wang (The University of Queensland, Australia)

15:50 – 16:00  O11 - ADAM17/IL-6 trans-signalling axis: a promising therapeutic target for lung adenocarcinoma - Mohamed I Saad (Hudson Institute, Australia)

* Sponsored sessions are organized by the scientific committee and the industry sponsor provides support without influence on topic, content or speakers.*
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00 – 16:30</td>
<td>COFFEE BREAK &amp; VISIT OF THE EXHIBITION</td>
<td>Grand Ballroom Foyer</td>
</tr>
<tr>
<td>16:30 – 18:30</td>
<td>SYMPOSIUM 5: CYTOKINES IN NEURONAL INFLAMMATION</td>
<td>Grand Ballroom A</td>
</tr>
<tr>
<td></td>
<td><strong>Sponsored by Biogen</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs: Douglas Golenbock and Burkhard Becher</strong></td>
<td></td>
</tr>
<tr>
<td>16:30 – 16:55</td>
<td>GM-CSF in tissue inflammation: Central communication conduit between T cells and phagocytes in immunopathology - <strong>Burkhard Becher (University of Zurich, Switzerland)</strong></td>
<td></td>
</tr>
<tr>
<td>16:55 – 17:20</td>
<td>The role of Interleukin-18 in Alzheimer’s-related seizure disorder</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- <strong>Douglas Golenbock (Umass Medical School, USA)</strong></td>
<td></td>
</tr>
<tr>
<td>17:20 – 17:45</td>
<td>Atypical signaling pathways induced by interferon gamma following viral infection of neurons</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- <strong>Glenn Rall (Fox Chase Cancer Center, USA)</strong></td>
<td></td>
</tr>
<tr>
<td>17:45 – 18:10</td>
<td>TREM2 and regulation of neuronal inflammation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- <strong>Marco Colonna, (Washington University, USA)</strong></td>
<td></td>
</tr>
<tr>
<td>18:10 – 18:30</td>
<td>O12 - Decoupling IL-6 biological effects using protein engineering</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- <strong>Ignacio Moraga Gonzalez (University Of Dundee, UK)</strong></td>
<td></td>
</tr>
<tr>
<td>18:20 – 18:30</td>
<td>O13 - Demystifying the mechanism of mitochondrial STAT3 activity</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- <strong>Daniel Gough (Hudson Institute, Australia)</strong></td>
<td></td>
</tr>
<tr>
<td>16:30 – 18:30</td>
<td>SYMPOSIUM 6: INTESTINAL HOMEOSTASIS</td>
<td>Grand Ballroom B</td>
</tr>
<tr>
<td></td>
<td><strong>Sponsored by Eli Lilly and Company</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chairs: Greg Sonnenberg and Manuela Raffatellu</strong></td>
<td></td>
</tr>
<tr>
<td>16:30 – 16:55</td>
<td>Cytokine regulation of intestinal health - <strong>Greg Sonnenberg (Weil Cornell, USA)</strong></td>
<td></td>
</tr>
<tr>
<td>16:55 – 17:20</td>
<td>Type III interferons control intestinal inflammation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- <strong>Ivan Zanoni (HMS, USA)</strong></td>
<td></td>
</tr>
<tr>
<td>17:20 – 17:45</td>
<td>Evasion of IL-22-mediated antimicrobial responses by bacterial pathogens</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- <strong>Manuela Raffatellu (UCSD, USA)</strong></td>
<td></td>
</tr>
<tr>
<td>17:45 – 18:10</td>
<td>Functional heterogeneity of IL-22 and IL-10 producing CD4 T cells</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- <strong>Nicola Gagliani (Hamburg, Germany)</strong></td>
<td></td>
</tr>
<tr>
<td>18:10 – 18:20</td>
<td>O14 - Critical role of IFNS in gastro-intestinal injury repair</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- <strong>Constance McElrath (Rutgers University, USA)</strong></td>
<td></td>
</tr>
<tr>
<td>18:20 – 18:30</td>
<td>O15 - NLRP1 inflammasome exacerbates inflammatory bowel disease through IL-18 production and dysbiosis of butyrate producing commensal clostridiales</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- <strong>Chien-Hsiung Yu (Walter and Eliza Hall Institute, Australia)</strong></td>
<td></td>
</tr>
<tr>
<td>18:30 – 20:30</td>
<td>DINNER BREAK - ON OWN</td>
<td></td>
</tr>
<tr>
<td>20:30 – 22:30</td>
<td>POSTER SESSION II with Wine, Beer and Snacks</td>
<td>Pavilion &amp; Grand Ballroom Foyer</td>
</tr>
</tbody>
</table>

* Sponsored sessions are organized by the scientific committee and the industry sponsor provides support without influence on topic, content or speakers.
### Monday, 29 October 2018

#### 08:30 – 10:35  
**PLENARY 2: ADVANCES IN PATHOGENIC TH17 AXIS OF EVIL**  
Grand Ballroom AB  
*Sponsored by Janssen Pharmaceuticals*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 – 09:05</td>
<td>Keynote Lecture 2: Oh to be seventeen again: IL-17 signaling in fungal immunity and autoimmune disease</td>
<td>Sarah Gaffen (UPMC)</td>
</tr>
<tr>
<td>09:05 – 09:30</td>
<td>Cytokine instruction of gene expression: a genomic view</td>
<td>John O’Shea (NIAMS, USA)</td>
</tr>
<tr>
<td>09:30 – 09:55</td>
<td>Crosstalk between tissue-Tregs and mesenchymal stromal cells</td>
<td>Diane Mathis (HMS, USA)</td>
</tr>
<tr>
<td>09:55 – 10:20</td>
<td>Environmental influences on intestinal homeostasis</td>
<td>Brigitta Stockinger (Francis Crick Institute, UK)</td>
</tr>
<tr>
<td>10:20 – 10:35</td>
<td>O16 - Type I interferons regulate B cell development and differentiation</td>
<td>Munir Akkaya (NIH, MD)</td>
</tr>
</tbody>
</table>

#### 10:35 – 11:00  
**COFFEE BREAK & VISIT OF THE EXHIBITION**  
Grand Ballroom Foyer

#### 11:00 – 12:35  
**SYMPOSIUM 7: TYPE II IMMUNITY**  
Grand Ballroom A  
*Chairs: Judith Allen and De’broski Herbert*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 11:25</td>
<td>Cytokine control of macrophage dynamics during helminth infection</td>
<td>Judith Allen (U. Manchester, UK)</td>
</tr>
<tr>
<td>11:25 – 11:50</td>
<td>Type 2 cytokine release from cDC2 critically regulates host protection and immunopathology</td>
<td>De’broski Herbert (UPenn, USA)</td>
</tr>
<tr>
<td>11:50 – 12:15</td>
<td>Comparative immunology to dissect immune responses during helminth infection and allergy</td>
<td>Elia Tait Wojno (Cornell, USA)</td>
</tr>
<tr>
<td>12:15 – 12:25</td>
<td>O17 - Allergic inflammatory memory of type 2 cytokines in human respiratory epithelial progenitor cells</td>
<td>Jose Ordovas-Montanes (Mit/Broad Institute/Ragon Institute, USA)</td>
</tr>
<tr>
<td>12:25 – 12:35</td>
<td>O18 - Tissue signals imprint ILC2 transcriptional identity and preemptive function</td>
<td>Steven Van Dyken (Washington University School of Medicine, USA)</td>
</tr>
</tbody>
</table>

#### 11:00 – 12:35  
**SYMPOSIUM 8: INNATE CYTOKINES AND CANCER**  
Grand Ballroom B  
*Sponsored by BioLegend*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 11:25</td>
<td>HMGB1 and other DAMPs in cancer and other diseases; therapeutic implication</td>
<td>Hideyuki Yanai (U. Tokyo, Japan)</td>
</tr>
<tr>
<td>11:25 – 11:50</td>
<td>Dichotomous functions of pattern recognition receptor and interferon signaling in cancer</td>
<td>Andy Minn (UPenn, USA)</td>
</tr>
<tr>
<td>11:50 – 12:15</td>
<td>Uncovering the pro-tumourigenic role of innate immune DNA sensors in cancer</td>
<td>Brendan Jenkins (Hudson Institute, Australia)</td>
</tr>
<tr>
<td>12:15 – 12:25</td>
<td>O19 - STAT3 suppresses primary tumour growth, but increases metastasis in MYC-driven small cell lung cancer</td>
<td>Aleks Camille Guanizo (Hudson Institute, Australia)</td>
</tr>
<tr>
<td>12:25 – 12:35</td>
<td>O20 - Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving IFN-y and IL-12</td>
<td>Christopher S Garris (Massachusetts General Hospital - Harvard Medical School, USA)</td>
</tr>
</tbody>
</table>

* Sponsored sessions are organized by the scientific committee and the industry sponsor provides support without influence on topic, content or speakers.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:35 – 14:00</td>
<td>LUNCH BREAK - ON OWN</td>
<td></td>
</tr>
<tr>
<td>12:45 – 13:45</td>
<td>BIOTECH/VENTURE CAPITAL PANEL DISCUSSION</td>
<td>Grand Ballroom A</td>
</tr>
<tr>
<td></td>
<td><em>Chair: Luke O’Neil</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>David Grayzel (Atlas Ventures), Samantha Truex (CEO of Quench), Ben Auspitz (Five Prime Capital Partners)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lunch provided to session attendees only</td>
<td></td>
</tr>
<tr>
<td>12:45 - 13:45</td>
<td>MEET THE EDITORS</td>
<td>Grand Ballroom B</td>
</tr>
<tr>
<td></td>
<td><em>Chair: Sri Devi Narasimhan</em></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sri Devi Narasimhan (Cell Press), Seth Scanlon (AAAS Science International, Inc.), Kavitha Scrannt (Immunity), Teodoro Pulvirenti (Journal Experimental Medicine), Laurie Dempsey (Nature Immunology)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lunch provided to session attendees only</td>
<td></td>
</tr>
<tr>
<td>14:00 – 16:00</td>
<td>SYMPOSIUM 9: IMMUNOREGULATION II</td>
<td>Grand Ballroom A</td>
</tr>
<tr>
<td></td>
<td><em>Chairs: Carla Rothlin and Mandy McGeachy</em></td>
<td></td>
</tr>
<tr>
<td>14:00 – 14:25</td>
<td>Regulating cytokine production and inflammation to control tuberculosis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Christina Stallings (Washington University, USA)</td>
<td></td>
</tr>
<tr>
<td>14:25 – 14:50</td>
<td>Energizing the troops: Th17 cell functions beyond classical inflammation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Mandy McGeachy (U. Pittsburg Medical School, USA)</td>
<td></td>
</tr>
<tr>
<td>14:50 – 15:15</td>
<td>Death begets a new beginning</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Carla Rothlin (Yale, USA)</td>
<td></td>
</tr>
<tr>
<td>15:15 – 15:40</td>
<td>Neuronal regulation of innate lymphoid cells</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Henrique Veiga-Fernandes (Instituto de Medicina Molecular, Portugal)</td>
<td></td>
</tr>
<tr>
<td>15:40 – 15:50</td>
<td>O21 - Interleukin-11 signaling induces a unique pathogenic CD4+ T helper-17 cell population</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Ka Yee Fung (Walter and Eliza Hall Institute, Australia)</td>
<td></td>
</tr>
<tr>
<td>15:50 – 16:00</td>
<td>O22 - The stromal tissue compartment as an orchestrator of IL-6-driven anti-microbial host defence</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Javier Uceda (Cardiff University, UK)</td>
<td></td>
</tr>
<tr>
<td>14:00 – 16:00</td>
<td>SYMPOSIUM 10: TYPE III AND OTHER IFNS</td>
<td>Grand Ballroom B</td>
</tr>
<tr>
<td></td>
<td><em>Chairs: Paul Hertzog and Carolyn Coyne</em></td>
<td></td>
</tr>
<tr>
<td>14:00 – 14:25</td>
<td>Molecular pathways that bifurcate type I and III interferon responses</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Ram Savan (U. Washington, USA)</td>
<td></td>
</tr>
<tr>
<td>14:25 – 14:50</td>
<td>Regulation of mucosal immunity to infection and cancer by interferon epsilon</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Paul Hertzog (Hudson Institute, Australia)</td>
<td></td>
</tr>
<tr>
<td>14:50 – 15:15</td>
<td>Antiviral signaling at the maternal-fetal interface</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Carolyn Coyne (U. Pittsburg Medical School, USA)</td>
<td></td>
</tr>
<tr>
<td>15:15 – 15:40</td>
<td>Combining TLR agonists for cancer therapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Bryan Williams (Hudson Institute, Victoria, AU)</td>
<td></td>
</tr>
<tr>
<td>15:40 – 15:50</td>
<td>O23 - IFN-lambda facilitates protective T cell immunity by modulation of migratory dendritic cell function during influenza virus infection</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Emily A Hemann (University Of Washington, USA)</td>
<td></td>
</tr>
</tbody>
</table>
O24 - Inactivation of type I interferon responses in the tumor microenvironment triggers the stromagenic switch and desmoplasia - Christina Cho (University Of Pennsylvania, USA)

16:00 – 16:30 COFFEE BREAK & VISIT OF THE EXHIBITION
Grand Ballroom Foyer

16:30 – 18:10 SYMPOSIUM 11: CYTOKINES AND CANCER II
Grand Ballroom A

Chairs: Steve Ziegler and Xiaoxia Li

16:30 – 16:55 IL-17 signaling in autoimmunity and cancer - Xiaoxia Li (Cleveland Clinic, USA)
16:55 – 17:20 Epithelial cytokines and cancer - Steve Ziegler (Benaroya Research Institute, USA)
17:20 – 17:45 Modulation of the Src/JAK/STAT3 axis within the complex tumour microenvironment: optimizing drug targeting in pancreatic cancer - Marina Pajic (Garvan Institute, Australia)
17:45 – 18:10 Anti-IL-1b in cancer immunotherapy - Reshma Singh (Novartis, USA)

16:30 – 18:10 SYMPOSIUM 12: TYPE I IFNS IN DISEASE
Grand Ballroom B

Sponsored by Boehringer Ingelheim*

Chairs: Daniel Stetson and Yanick Crow

16:30 – 16:55 Induction of the type I interferon response - Daniel Stetson (U. Washington, USA)
16:55 – 17:20 Nucleic acid driven inflammation in humans - Yanick Crow (U. Manchester, UK)
17:20 – 17:45 The role of Interferon alpha in CNS lupus - Michael Carroll (HMS, USA)
17:45 – 18:10 Blockade of Type I IFNs in SLE - Kerry Casey (MedImmune)

19:00 – 23:00 CONFERENCE DINNER – SPIRIT OF BOSTON CRUISE
Sponsored by Janssen Pharmaceuticals

Tuesday, 30 October 2018

08:30 – 10:30 SYMPOSIUM 13: PHILIP I. MARCUS SYMPOSIUM
Grand Ballroom A

Sponsored by Mary Ann Liebert, Inc.*

Chairs: Ganes Sen and Michael Gale

08:30 – 08:55 Immune programming by RIG-I-like receptors and cytokine crosstalk - Michael Gale (U. Washington, USA)
08:55 – 09:20 Mechanisms of innate sensing and signaling by RIG-I-like receptors - Michaela Gack (U. Chicago, USA)
09:20 – 09:45 EGFR is needed for eliciting innate immune signaling by intracellular nucleic acid recognizing receptors - Ganes Sen (Cleveland Clinic, USA)
09:45 – 10:10 Inhibition of viral replication by interferon stimulated genes - John Schoggins (UTSW, USA)
10:10 – 10:20 O25 - Type I interferon sensing unlocks dormant adipocyte inflammatory potential - Senad Divanovic (Cincinnati Children’s Hospital Medical Center, USA)
10:20 – 10:30 O26 - The long non-coding RNA LUCAT1 transcriptionally regulates type-I interferon responses - Shiuli Agarwal (University of Massachusetts, USA)

* Sponsored sessions are organized by the scientific committee and the industry sponsor provides support without influence on topic, content or speakers.
# SYMPOSIUM 14: DERMAL RESPONSES, CYTOKINES

**Grand Ballroom B**

**Sponsored by PBL Assay Science***

**Chairs:** John Harris and Jennifer Towne

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 – 08:55</td>
<td>Cytokines promote the localization and survival of autoreactive T cells in skin lesions of vitiligo patients - John Harris (UMass Medical School, USA)</td>
</tr>
<tr>
<td>08:55 – 09:20</td>
<td>Neuroimmune regulation of skin inflammation - Brian Kim (Washington University, USA)</td>
</tr>
<tr>
<td>09:20 – 09:45</td>
<td>To ubiquitinate or deubiquitinate, that is the question - Daniel Kastner (NIH, USA)</td>
</tr>
<tr>
<td>09:45 – 10:10</td>
<td>Regulation and function of interleukin-36 - Jennifer Towne (Janssen Pharmaceuticals, USA)</td>
</tr>
<tr>
<td>10:10 – 10:20</td>
<td>O27 - A long noncoding RNA attenuates dendritic cell cytokine production and decreases autoimmune disease susceptibility - Tom Brodnicki (St Vincent's Institute, Australia)</td>
</tr>
<tr>
<td>10:20 – 10:30</td>
<td>O28 - AIM2-deficient dendritic cell vaccine facilitates adoptive T-cell therapy and anti-PD-1 immunotherapy via the activation of sting-type I IFN signalling - Keitaro Fukuda (University Of Massachusetts Medical School, USA)</td>
</tr>
</tbody>
</table>

# COFFEE BREAK & VISIT OF THE EXHIBITION

**Grand Ballroom Foyer**

# SYMPOSIUM 15: INFLAMMASOME AND IL1 FAMILY MEMBERS II

**Grand Ballroom A**

**Sponsored by Surface Oncology***

**Chairs:** Jonathan Kagan and Cem Gabay

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 11:25</td>
<td>O29 - The expanding functions of inflammasomes complexes - Vijay Rathinam (UConn, USA)</td>
</tr>
<tr>
<td>11:25 – 11:50</td>
<td>Regulation of innate immune signaling - Jonathan Kagan (Childrens Hospital Boston, USA)</td>
</tr>
<tr>
<td>11:50 – 12:15</td>
<td>IL18 and IL18BP in macrophage activation syndrome - Cem Gabay (University of Geneva, Switzerland)</td>
</tr>
<tr>
<td>12:15 – 12:25</td>
<td>O30 - The NLRC4 inflammasome requires IRF8-dependent production of NAIPS - Rajendra Karki (St. Jude Children’s Research Hospital, USA)</td>
</tr>
<tr>
<td>12:25 – 12:35</td>
<td>O31 - Germ-cell specific inflammasome component NLRP14 negatively regulates cytosolic nucleic acid sensing to promote fertilization - Sagi Shapira (Columbia University, USA)</td>
</tr>
</tbody>
</table>

# SYMPOSIUM 16: INFECTION AND IMMUNITY

**Grand Ballroom B**

**Sponsored by AAAS***

**Chairs:** Hiroki Yoshida and Katrin Mayer-Barber

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 11:25</td>
<td>Novel immune evasion strategy of P. gingivalis via inhibitory receptor, siglec - Hiroki Yoshida (Saga University, Japan)</td>
</tr>
<tr>
<td>11:25 – 11:50</td>
<td>IL-27 - Still inhibiting after all these years - Chris Hunter (UPenn, USA)</td>
</tr>
<tr>
<td>11:50 – 12:15</td>
<td>Innate inflammatory cytokines and effector cells in host resistance to tuberculosis - Katrin Mayer-Barber (NIAID, NIH)</td>
</tr>
<tr>
<td>12:15 – 12:25</td>
<td>O32 - The multifaceted M152 protein selectively modulates sting-dependent signaling to enhance murine cytomegalovirus replication - Melanie M Brinkmann (Helmholtz Centre For Infection Research, Germany)</td>
</tr>
<tr>
<td>12:25 – 12:35</td>
<td>O33 - Activation of mitochondrial apoptotic signaling triggers NLRP3 inflammasome activation - Kate E Lawlor (Hudson Institute, Australia)</td>
</tr>
</tbody>
</table>

* Sponsored sessions are organized by the scientific committee and the industry sponsor provides support without influence on topic, content or speakers.
### SESSION A - Cancer
Grand Ballroom A

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:55 – 13:00</td>
<td>O34 - IL-38 restricts anti-tumor immunity by limiting IL-17 production from gamma-delta T cells through IL1RAPL1</td>
<td>Javier Mora (University of Costa Rica, Costa Rica)</td>
</tr>
<tr>
<td>13:00 – 13:10</td>
<td>O35 - Significant reduction of tumor growth and metastasis by intratumor treatment of a shRNA targeting IL-17RA in a murine B16F10 melanoma model</td>
<td>Ya-Shan Chen (Chang Gung University, Taiwan)</td>
</tr>
<tr>
<td>13:20 – 13:30</td>
<td>O37 - ELF5 regulated interferon signaling in triple negative breast cancer</td>
<td>Rumela Chakrabarti (University of Pennsylvania, USA)</td>
</tr>
<tr>
<td>13:30 – 13:40</td>
<td>O38 - Myeloid P38 MAPK promotes tumorigenesis by suppressing cytotoxic T cell recruitment</td>
<td>Min-Kyung Choo (Massachusetts General Hospital and Harvard Medical School, USA)</td>
</tr>
</tbody>
</table>

### SESSION B - Innate Immunity
Grand Ballroom B

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:55 – 13:00</td>
<td>O39 - A programmable signaling complex controls cell fate decisions upon toll-like receptor activation</td>
<td>Yunhao Tan (Boston Children’s Hospital, Harvard Medical School, USA)</td>
</tr>
<tr>
<td>13:00 – 13:10</td>
<td>O40 - A new antiviral ISG TDRD7 inhibits cellular autophagy to control virus replication</td>
<td>Saurabh Chattopadhyay (University of Toledo College of Medicine and Life Sciences, USA)</td>
</tr>
<tr>
<td>13:10 – 13:20</td>
<td>O41 - New tricks for an old dog: non-canonical STAT3 mediates TLR4 mitochondrial reprogramming and inflammation</td>
<td>Ashley Mansell (Hudson Institute, Australia)</td>
</tr>
<tr>
<td>13:20 – 13:30</td>
<td>O42 - The moonlighting protein 14-3-3 ETA controls MDA5 activation and the MDA5-dependent antiviral innate immunity</td>
<td>Helene Minyi Liu (National Taiwan University, Taiwan)</td>
</tr>
<tr>
<td>13:30 – 13:40</td>
<td>O43 - Important differences in the IFN-I response to DNA and RNA virus particles</td>
<td>David Hare (Mcmaster University, Canada)</td>
</tr>
</tbody>
</table>

### SESSION C - Cytokine Regulation
Grand Ballroom C

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:55 – 13:00</td>
<td>O44 - IL-27P28 is an antagonist of B cell response during toxoplasmosis</td>
<td>Jeongho Park (University Of Pennsylvania, USA)</td>
</tr>
<tr>
<td>13:00 – 13:10</td>
<td>O45 - IL-36 cytokines alter the composition of the intestinal microbiome to protect against obesity and metabolic dysfunction</td>
<td>Eirini Giannoudaki (Trinity College Dublin, Ireland)</td>
</tr>
<tr>
<td>13:10 – 13:20</td>
<td>O46 - Placenta-specific 8 suppresses interferon gamma production by TH1 cells</td>
<td>Chris D Slade (University of Georgia, USA)</td>
</tr>
<tr>
<td>13:20 – 13:30</td>
<td>O47 - Epigenetic landscape of FOXP3 enhancer sites during thymic FOXP3+ TREG development of CNS0- and CNS3-deficient mice</td>
<td>Ryoji Kawakami (Osaka university, Japan)</td>
</tr>
</tbody>
</table>
13:40 – 13:50  O48 - HIPPO/MST signaling couples metabolic state and function of CD8A+ dendritic cells for cytotoxic T-cell priming - Xingrong Du (St. Jude Children’s Research Hospital, USA)

14:00 – 15:35  SYMPOSIUM 17: T CELL REGULATION IN CANCER  Grand Ballroom A

Chairs: Ananda Goldrath and Wenjun Ouyang

14:00 – 14:25  Transcriptional regulation of T cell residency in tissues and tumors - Ananda Goldrath (UCSD, USA)

14:25 – 14:50  Chemokines in cancer immunotherapy - Andrew Luster (HMS, USA)

14:50 – 15:15  Cytokine pathways on tumor infiltrating T cells revealed by single cell RNAseq - Wenjun Ouyang (Amgen, USA)

15:15 – 15:25  O49 - Cytokine and transcriptional regulation of stem cell-like CD8 T cells - Tuoqi Wu (NIH, USA)

15:25 – 15:35  O50 - IL-17 drives the bio-energetic activity of lymph node fibroblastic reticular cells to promote expansion during TH17 cell activation - Saikat Majumder (University of Pittsburgh, USA)

14:00 – 15:40  SYMPOSIUM 18: CYTOKINES: BEYOND THE AGE OF DISCOVERY  Grand Ballroom B

Sponsored and organized by Japanese Society for Interferon and Cytokine Research (JSICR)*

Chairs: Akinori Takaoka and Chris Hunter

14:00 – 14:25  Th2 cytokines in allergic responses; from Th2 to ILC2 - Masato Kubo (Tokyo University of Science, Japan)

14:25 – 14:50  Gateway reflex, a new concept in Neuroimmunology coming from IL-6 discovery - Daisuke Kamimura (Hokkaido University, Japan)

14:50 – 15:15  Resolution of inflammation and tissue repair by immunoregulatory monocytes - Masato Tanaka (Tokyo University, Japan)

15:15 – 15:40  Interferons and innate immunity - Akinori Takaoka (Hokkaido University, Japan)


15:55 – 17:25  PLENARY 3: TISSUE SPECIFIC RESPONSES - GUT, LUNG AND LYMPH NODES  Grand Ballroom A

Sponsored by The Kenneth Rainin Foundation*

Chair: Eleanor Fish

15:55 – 16:25  ICIS BioLegend William E. Paul Awardee Lecture From cytokines to bugs - Giorgio Trinchieri (NCI, NIH, USA) Bill Paul Awardee

16:25 – 16:50  Control of tissue immunity and repair by the microbiota - Yasmine Belkaid (NIH, USA)

16:50 – 15:25  Keynote Lecture 3 Cytokine regulation of chronic inflammation - David Artis (Cornell, NY, USA)

17:25 – 17:30  CONFERENCE WRAP UP – Invitation to Cytokines 2019 in Vienna  Grand Ballroom A

* Sponsored sessions are organized by the scientific committee and the industry sponsor provides support without influence on topic, content or speakers.
POSTER SESSIONS

Poster session 1 - Saturday, 27 October 2018

Anti-cytokine therapy


P002 TRANSCRIPTIONAL PROFILES OF SYNOVIAL BIOPSIES PREDICT THERAPEUTIC RESPONSE TO BIOLOGICS IN RHEUMATOID ARTHRITIS / B. Cossins* - R. Andrews - J. Twohig - N. Williams - G. Jones - S. Jones


P004 PREDICTING TNFALPHA INHIBITOR TREATMENT RESPONSE USING CYTOKINES IN PATIENTS WITH RHEUMATOID ARTHRITIS / M. N. Lassere* - J. Gu - S. Baker


P008 TOWARDS THE STRUCTURE OF INTERLEUKIN-27, MEMBER OF THE IL-12 FAMILY / K. Skladanowska* - Y. Bloch - S. Savvides


Autoinflammation and autoimmunity


P014 IL-17A SIGNALING TO SCA-1+ CARDIAC FIBROBLASTS INDUCES GM-CSF AND PROMOTE DEVELOPMENT OF HEART FAILURE / D. Cihakova* on behalf of Cihakova lab


P018 AIM2 INFLAMMASOME IS ACTIVATED IN THE SALIVARY GLAND DERIVED FROM PATIENTS WITH PRIMARY SJOGREN’S SYNDROME / S.-M. Hong* - J. Lee - S. G. Jang - S. Kwok - S.-H. Park

P019 COLLAGEN-INDUCED ARTHRITIS, AN ANIMAL MODEL OF RHEUMATOID ARTHRITIS, IS AMELIORATED BY INJECTION OF AN ENZYMES CAPABLE OF MODIFYING TERMINAL SUGARS / T. Kaifu* - S.-H. Chung - Y. Iwakura


P020.B THE ROLE OF EPIGENETIC MODIFICATIONS IN DIABETIC COMPLICATIONS / M. Chattopadhyay - C. Levin* - V. Thankur


Cytokine regulation


P022 B CELL SPECIFIC IL-6 PRODUCTION PLAYS A PARADOXICAL ROLE IN B CELL DIFFERENTIATION / M. Akkaya* - S. K. Pierce

P023 ACTIVE TYPE I IFN SIGNALING IN ABSENCE OF DETECTABLE CYTOKINE / J. Altman* - J. Taft - D. Bogunovic


P025 IL-33 STIMULATING HUMAN MAST CELL CHEMOKINE VIA MAPK ACTIVATION, AND INHIBITION BY TETRAMETHOXYLUTEOLIN / M. Bawazeer* - T. Theoharides


P027 MECHANISM OF GP130 ACTIVATION AND REGULATION OF ITS DOWNSTREAM SIGNALLING / F. Dehkhoda* - N. Durisic - Y. Chhabra - A. Brooks


P032  DNA METHYLATION IMPAIRS MONOCYTE FUNCTION IN TUBERCULOSIS LEADING TO DISEASE PROGRESSION / F. A. Zambuzi - M. S. Espindola - L. S. Soares - L. J. Galvão-Lima - R. C. Castro - F. G. Frantz* on behalf of Laboratory of Immunology and Epigenetic


P034  MANIPULATING IL-10 IMMUNO-MODULATORY PROPERTIES BY FINE-TUNING ITS RECEPTOR BINDING PROPERTIES / C. Gorby* - P. Fye - J. Martinez-Fabregas - E. Pohler - S. Wilmes - I. Moraga-Gonzalez

P035  REGULATION OF IL-17A EXPRESSION DURING TOXOPLASMA GONDII INFECTION IN RETINAL CELLS / F. Fahmi-Bittich - V. Greigert* - A. W. Pfaff - E. Candolfi - J. Brunet

P036  STAT3 SUPPRESSES PRIMARY TUMOUR GROWTH, BUT INCREASES METASTASIS IN MYC-DRIVEN SMALL CELL LUNG CANCER / A. C. Guanizo* - J. Chen - S. Jayasekara - D. N. Watkins - D. J. Gough


P038  CYTOKINE EXPRESSION VARIABILITY ACROSS CELLS AND SPECIES SHAPES INNATE IMMUNITY / T. Hagai* - S. A. Teichemann

P039  THE GESTATIONAL CYTOKINE LEUKEMIA INHIBITORY FACTOR (LIF) CAN DEACTIVATE GAMMA-INTERFERON (IFNG)-TREATED MACROPHAGES, PROMOTING TROPHOBLAST MIGRATION AND INVASION IN VITRO / J. Hamelin Morrissette* - C. Vaillancourt - C. Reyes-Moreno

P040  THE INFLUENCE OF IFNL4 SINGLE NUCLEOTIDE POLYMORPHISMS ON IFNL3 EXPRESSION / R. Hartmann* - M. Møhlenberg - E. Terczynska-Dyla

P041  HISTONE H2A.Z SUPPRESSION OF INTERFERON-STIMULATED TRANSCRIPTION AND ANTIVIRAL IMMUNITY IS MODULATED BY GCN5 AND BRD2 / C. M. Horvath* - N. Au-Yeung

P042  ADENOSINE MONOPHOSPHATE-ACTIVATED PROTEIN KINASE REGULATES MITOCHONDRIAL METABOLIC CHANGES CRITICAL TO THE PRODUCTION OF TYPE I INTERFERON BY PRIMARY HUMAN PLASMACYTOID DENDRITIC CELLS / H. J. Hurley* - P. Fitzgeral-Bocarsly

P043  IL-27 TRIGGERS AUTOPHAGY IN MACROPHAGES VIA A MTOR AND LC3-INDEPENDENT MANNER / F. Jang* - J. Zhang - K. Nagashima - H. C. Lane - T. Imamichi*

P044  REGULATION OF ENDOGENOUS INTERLEUKIN-36 ACTIVITY / A. A. A. A. A.

P045  REGULATION OF ENDOGENOUS INTERLEUKIN-36 ACTIVITY / A. A. A. A.

P046  THE OPPOSING EFFECTS OF IFN-GAMMA VS. IFN-ALPHA ON IL-12 AND TNF SECRETION BY HUMAN PRIMARY MONOCYTES / A. Muglia Thomaz da Silva Amancio - L. Mittereder - L. Carletti - A. Sher - D. Jankovic*

P047  CROHN'S DISEASE-ASSOCIATED EPIGENETIC READER SP140 ORCHESTRATES IMMUNE CELL IDENTITY THROUGH REPRESSION OF CHROMATIN ACCESSIBILITY / K. Jeffrey* - H. Amatullah - S. Digumarti


P048.B  ANCHOMANES DIFFORMIS; A POTENTIAL THERAPEUTIC AGENT TO INCREASED INFLAMMATION IN TYPE II DIABETES AND COMPLICATIONS / T. D. Alabi* - N. L. Brooks - O. O. Gountibejü on behalf of Phytomedicine & Phytochemistry Group


Cytokines in cancer development and antitumor immune therapy

P049  INTERFERON SIGNALING CONFER INTRINSIC RESISTANCE TO ANDROGEN DEPRIVATION THERAPY IN METASTATIC PROSTATE CANCER / S. Agarwal* - K. McGowen - F. Elloumi - M. Cam - M. Beshiri - E. Corey - K. Kelly


P052  IFN-REGULATED TUMOR SUPPRESSION VIA MITOCHONDRIAL PROTEINS / D. V. Kalvakolanu*

P053  NK CELLS SHAPE TUMOR MICROENVIRONMENT BY TARGETING AND DIFFERENTIATING CANCER STEM CELLS/POORLY DIFFERENTIATED TUMORS AND AUGMENTING TUMOR INHIBITORY IMMUNE EFFECTORS; ROLE IN INHIBITION OF METASTASIS / K. Kaur* - A. Jewett - Y. Shi

P054  OBTAINING AND ENRICHMENT OF ANTIGEN-SPECIFIC CYTOTOXIC T LYMPHOCYTES WITH CYTOTOXIC ACTIVITY AGAINST HER2-EXPRESSION TUMOR CELLS / M. Kuznetsova* - J. Lopatnikova - S. Sennikov


P057  A NOVEL CYTOKINE-CONTROLLED IMMUNE CHECKPOINT IN CHRONIC LYMPHOCYTIC LEUKAEMIA / B. Garci1an - D. Easton - W. Figgett - M. Le Page - A. Wei - S. Ting - C. Croce - C. Tam - F. Mackay*

P058  ANALYSIS OF IL-17A AND IL-17F EXPRESSION IN APCMIN MOUSE INTESTINAL CANCER MODEL / Y. Makusheva* - S. Kakuta - C. Tang - Y. Iwakura


P060  PD-1 SIGNALING IMPACTS T CELL FUNCTION AND TOXOPLASMA GONDII PARASITE BURDEN DURING BOTH EARLY AND CHRONIC PHASES OF INFECTION / J. A. Perry*
**Innate immunity**


P062  AN APIAP2 TRANSCRIPTION FACTOR ALTERS THE DEVELOPMENT OF HOST IMMUNE RESPONSE BY MODULATING IFN-GAMMA SECRETION / M. Akkaya* - A. Bansal - P. W. Sheehan - C. K. Cimperman - L. H. Miller - S. K. Pierce


P065  UNDERSTANDING RIG-I ACTIVATION BY SELF-RNA IN INNATE IMMUNITY / R. Ancar* - H. Himmighoefer - J. R. Hesselberth

P066  LINCRNAS AND RNA-DEPENDENT GENE REGULATION IN INNATE IMMUNITY / M. K. Atianand* - M. J. Menk - S. Lal


P068  A NOVEL MOLECULAR MECHANISM OF INFLAMMATION INVOLVING AP1 TRANSCRIPTION FACTOR / M. S. Baig*


P071  SUBCELLULAR POSITIONING OF INNATE IMMUNE SENSORY PROTEINS IS IMPORTANT FOR THEIR FUNCTIONS / K. C. Barnett* - J. C. Kagan


P073  HIGH RESOLUTION KINETIC CHARACTERIZATION OF RIG-I MEDIATED INTERFERON INDUCTION, INTERFERON SIGNALING AND ISG INDUCTION / J. Frankish - D. Schweinoch - C. Sparn - S. Niesik - S. Bastian - J. Willemsen - L. Kaderali - M. Binder*


P076  HIGH THROUGHPUT CRISPR SCREENING IDENTIFIES GENES CRITICAL FOR MACROPHAGE SURVIVAL AND FUNCTION / S. Carpenter* - S. Covarrubias - M. Boettcher - M. McManus

P077  HUMAN MACROPHAGE POLARIZATION IN THE RESPONSE TO MYCOBACTERIUM LEPRAE DNA / K. van Huss - B.-Y. Hong - M. Rodriguez - J. C. Kagan


P079  INTERLEUKIN-12 P80 / Y. C. Bloch* - S. Savvides


P081  HUMAN MACROPHAGE POLARIZATION IN THE RESPONSE TO MYCOBACTERIUM LEPRAE DNA / K. van Huss - B.-Y. Hong - M. Rodriguez - J. C. Kagan

P082  VALIDATION THE ROLE OF CTRP6 IN CHRONIC KIDNEY DISEASE PROGRESSION / H. H. Chi* - M. A. Murayama - Y. Iwakura
P083  CYTOMEGALOVIRUS IE1 PROTEIN TARGETING PML BODIES IS ESSENTIAL FOR TROPHOBLAST INFECTION BUT PP65 OR PP71 TARGETING IFI16 AND DAXX ARE DISPENSABLE / K. Y. Choi* - J. Hornig - A. McGregor

P084  IL-33 AMPLIFIES THE INNATE INFLAMMATORY RESPONSE TO T. GONDII / J. T. Clark* - D. Christian - J. Park - M. Jacquet - J. Silver - C. Hunter


P086  ELF1 ELICITS A NOVEL TRANSCRIPTIONAL PROGRAM WITH BROAD ANTIVIRAL ACTIVITY, WHICH FUNCTIONS INDEPENDENTLY OF THE IFN RESPONSE / L.-L. Seifert - S. Ballentine - A. Briley - C. Si - M. deVries - D. Saha - B. Rosenberg - S. Tripathi - M. Dittmann*

P087  INTERFERON-BETA AMPLIFIES IL-10 PRODUCTION BY MACROPHAGES IN A STAT1-DEPENDENT MANNER TO FEEDBACK INHIBIT ITS OWN EXPRESSION / H. Dickensheets - N. Lee - F. Sheikh - D. Ireland - A. Gamero - R. P. Donnelly*

P088  OXIDIZED PHOSPHOLIPIDS AS INNATE IMMUNE MODULATORS / M. Ernandes* - J. Kagan


P090  MOLECULAR DETERMINANTS OF PHAGOCYTE HYPERACTIVATION / C. L. Evavold* - J. Ruan - Y. Tan - S. Xia - H. Wu - J. Kagan

P091  THE OFF-TARGET EFFECTS OF VACCINES: BENEFITS AND COLLATERAL DAMAGE / E. N. Fish*

P092  POSITIVE REGULATION OF VIRUS INDUCED-INNATE IMMUNE SIGNALING BY THE E3 UBIQUITIN LIGASE TRIM65 / D. N. Fonseca* - G. Pisanelli - A. Garcia-Sastre


P095  THE ROLE OF TYPE 1 AND 3 INTERFERONS IN OCULAR TOXOPLASMOSIS / V. Greigert* - F. Fahmi-Bittich - J. Brunet - E. Caron - N. Grandvaux


P099  PROSTAGLANDIN E2 IS AN INHIBITORY DAMAGE ASSOCIATED MOLECULAR PATTERN WHICH CRITICALLY REGULATES STERILE INFLAMMATION-RELATED DISEASES INDUCED BY DEAD CELLS / S. Hangai* - H. Yanai - T. Taniguchi

P100  THE HOST-ANTIVIRAL PROTEIN VIPERIN ENHANCES THE DSDNA SIGNALLING PATHWAY VIA A DIRECT INTERACTION WITH STING / K. M. Crosse - E. Monson - M. Smith - K. Van der Hoek - P. Revill - M. Beard - H. Helbig*


P102  THE ROLE OF TYPE 1 AND 3 INTERFERONS IN OCULAR TOXOPLASMOSIS / V. Greigert* - F. Fahmi-Bittich - J. Brunet - E. Caron - N. Grandvaux

P103  REPURPOSING OF CARDIOVASCULAR DRUGS FOR THE TREATMENT OF IL-1 MEDIATED DISEASE / F. Humphries* - K. Fitzgerald
P104  INTERFERON-ALPHA/BETA SIGNALING IN NEURONS MEDIATES PROTECTION AGAINST VIRAL ENCEPHALOMYELITIS AND REGULATES INTERFERON-GAMMA DEPENDENT RESPONSES / M. Hwang* - C. Bergmann


P106  4-1BB EXPRESSION ON MAIT CELLS IS ASSOCIATED WITH ENHANCED IMMUNE RESPONSES THAT ARE DEPENDENT ON IL-2 / J. Jiang* - X. Cheng

P107  ORGANISINAL NETWORKS OF PROTECTION ACROSS TISSUES DURING VACCINATION / M. Kadoki* - N. Chevrier

P108  MAVS-DEPENDENT INDUCTION OF INNATE IMMUNE RESPONSES IN HANTAAN VIRUS INFECTION / A. Kell* - E. Hemam - B. Turnbull - M. Gale


P110  CG103 UPREGULATES NADPH OXIDASE-INDUCED REACTIVE OXYGEN SPECIES UPON TLR2 STIMULATION IN MACROPHAGES / T.-H. Kim* - H.-C. Lee - J.-S. Lee

P111  VIRAL RNA RECOGNITION BY TLR7 AND MAVS CONTROLS CD8 T CELL RESPONSE / M. Kim* - P. Pillai - H. Dong - A. Iwasaki


P115  IL-33 REGULATES THE ADJUVANT EFFECT OF HYDROXYPROPYL-B-CYCLODEXRIN (HP-B-CD) IN THE LUNG / T. Kusakae* - S. Kobari - E. Kuroda - K. Ishii

P116  INTRACELLULAR CALCIUM REGULATES THE STING SIGNALING PATHWAY / D. Kwon* - H. Sesaki - S.-J. Kang

P117  ZIKA VIRUS INFECTS HUMAN MICROGLIAL CELLS AND ACTIVATES TYPE III INTERFERON RESPONSE FOR HOST ANTIVIRAL MECHANISM / A. Selim - S. Lee*


P119  THE ROLE OF PSTPIP2 AND INNATE IMMUNITY IN LISTERIA MONOCYTOGENES INFECTION / R. Geiger* - T.-D. Kanneganti


P119.E  SG INHIBITS HBV REPLICATION THROUGH SAM DOMAIN DEPENDENT SUPRESSION OF VIRAL RNA TRANSLATION / Y. Wang* - X. Fan - Y. Song - J. Han


**Mucosal immunity**

**P120** DIVERGENT IMMUNOMODULATORY CAPACITY OF THE HEALTHY VERSUS IBD HUMAN ENTERIC VIROME / F. Adiliaghdam* - T. L. Saunders - H. Rivas - K. L. Jeffrey


**P122** INTESTINAL CD4 T-CELL RESPONSES TO ORAL VACCINATION / A. Bhattacharjee* - J. Ji - J. Tometich - N. Rittenhouse - A. Pooholek - O. Harrison - J. Linehan - Y. Belkaid - T. Hand


**P124** INNATE SOURCES OF INTERFERON-GAMMA MEDIATE PROTECTIVE RESPONSES TO CRYPTOSPORIDIUM INFECTION / J. Gullicksrud* - A. Sateriale - J. Clark - C. Hunter - B. Striepen

**P125** HUMANIZED CEREBLON MICE REVEALED DIFFERENT THERAPEUTIC PATHWAYS OF IMMUNOMODULATORY DRUGS FOR MALIGNANCY AND INFLAMMATION / Y. G. Hailu* - D. Millr ine - T. Kishimoto

**P126** STAT1 SIGNALING SHIELDS T CELLS FROM NK CELL MEDIATED CYTOTOXICITY TO PROMOTE INTESTINAL INFLAMMATION / Y. H. Kang* - A. Biswas - S. Snapper

**P127** THE IMPORTANCE OF IL-17A/IL-17RA AX I S IN HOST DEFENSE DURING CHRONIC RESPIRATORY INFECTIONS / C. Cigan a - B. Sipione - G. Rizzo - M. Melessike - J. A. Mertz - J. K. Kolls - A. Bragonzi - N. I. Lore

**P128** COMMENSAL GUT FUNGI REGULATE SUSCEPTIBILITY TO COLITIS AND COLORECTAL CANCER. / A. Malik* - D. Sharma - C. Guy - T.-C. Chang - S. Olsen - G. Neale - P. Vogel - T.-D. Kanneganti


**P130** NON-MIGRATORY LUNG DCS SUBSETS MEDIATE CYCLIC DI-GMP ADJUVANT ACTIVITY ON THE MUCOSAL SURFACE / S. Mansouri* - D. S. Katikaneni - S. schattgen - K. Fitzg e rald - L. Jin

**P131** TUFT CELL DEVELOPMENT AND FUNCTION IN THE BILIARY SYSTEM / C. O’leary* - C. Schneider - R. Locksley


**P133** MICROBIOTA DEPENDENT EFFECTS OF INTERLEUKIN-22 IN COLITIS / P. Pelczar* - M. Sabih i - M. Böttcher - N. Gagliani - S. Huber

**P134** CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE EXPLOIT IFN-LAMBDA SIGNALING TO INVADE ACROSS THE AIRWAY EPITHELIUM / M. A. Wickersham* - D. Ahn - A. Prince
T cell differentiation and function


P135 NKG2D MODULATES THE PROINFLAMMATORY FEATURES OF TH1 AND TH17 CELLS AND CONTRIBUTES TO THEIR PATHOGENICITY IN VIVO / M. Babic Cac* - F. Heinrich - Q. Hammer - B. Polic - C. Romagnani


P137 TGF-B1 SIGNALING PROMOTES IL-22 PRODUCTION BY TH17 CELLS / L. Garcia Perez* - P. Pelzcar - J. Kemptsi - N. Galgiani - S. Huber


P139 CCDC134 FACILITATES T CELL ACTIVATION AND INFLAMMATORY RESPONSES BY REGULATING T-CELL RECEPTOR SIGNALING / J. Huang* - T. Zhang - B. Yu - Y. Wang - S. Yin - X. Qiu


Poster session 2 - Sunday, 28 October 2018

Autoinflammation and autoimmunity


P144 GLYCA AS A NOVEL CANDIDATE BIOMARKER FOR RESPONSE TO INTERFERON-BETA AND NATALIZUMAB TREATMENT IN MULTIPLE SCLEROSIS / D. M. Pineda* - T. Dierckx - B. Pignolet - R. Liblau - D. Brassat - J. Van Weyenbergh

P145 PREFERENTIAL RECOGNITION OF ADVANCED GLYCATION END PRODUCTS BY SERUM ANTIBODIES AND LOW-GRADE SYSTEMIC INFLAMMATION IN DIABETES MELLITUS AND ITS COMPLICATIONS / A. Raghav* - J. Ahmad

P146 CROSSTALK BETWEEN TLR7 AND IFNG SIGNALING VIA STAT1 IN B CELLS CONTROLS SPONTANEOUS GERMINAL CENTER AND AUTOIMMUNE RESPONSES / Z. Rahaman* - S. B. Chodissetti - P. P. Domeier - N. Choi - T. Decker

P147 IFNAR SIGNALING IN RADIOTHERESISTANT CELLS IS REQUIRED TO SUPPRESS ORGAN-SPECIFIC AUTOIMMUNITY IN VITILIGO / R. L. Riding* - J. M. Richmond - K. Fukuda - J. E. Harris


P149 LOCAL PRODUCTION OF INTERFERON GAMMA AND FAS LIGAND IN THE SKIN ARE REQUIRED FOR MELANOCYTE CLEARANCE IN VITILIGO / J. P. Strassner* - J. M. Richmond - V. N. Azzolino - X. Fan - J. E. Harris
Cytokine regulation

P154 SPATIOTEMPORAL ACTIVATING OF A MAMMARY PRIMARY SUPER-ENHANCER CONTROLS SECONDARY ENHANCERS AND GENE EXPRESSION DURING PREGNANCY / H. K. Lee*

P155 A HIGH FAT DIET RESCUES SHORTENED LIFESPAN AND CACHEXIA-LIKE PHENOTYPES BY MODULATING INSULIN SIGNALING IN SIRT6 DEFICIENT MOUSE / Z. Li* - K. Xu - Q. Liu - Z. Wang


P158 EXTRACELLULAR VESICLES ARE INCREASED IN THE SERUM OF CHILDREN WITH AUTISM SPECTRUM DISORDER, CONTAIN MITOCHONDRIAL DNA, AND STIMULATE HUMAN MICROGLIA TO SECRETE IL-1BETA / I. Tsilioni* - T. C. Theoharides

P159 EXTRACELLULAR ADP/P2Y1 AXIS MEDIATES CXCL-2 INDUCED NEUTROPHIL CHEMOTAXIS IN RHEUMATOID ARTHRITIS / X. Zhang* - M. Qian

P160 RNA BASE MODIFICATIONS REGULATE THE TYPE I INTERFERON RESPONSE / M. Mcfadden* - A. McIntyre - N. Gokhale - C. Mason - S. Horner


P162 CD206 M2-LIKE MACROPHAGES REGULATE WHITE AND BEIGE PROGENITORS / A. Nawaz* - Y. Igarashi - T. Kado


P167 DEMONSTRATION OF THE REGULATORY ROLE OF LEUKEMIA INHIBITORY FACTOR (LIF) AND ONCOSTATIN M (OSM) IN THE RESPONSE OF HUMAN TROPHOBLASTS TO PRO-INFLAMMATORY SIGNALS / M. Ravelojaona* - J. Hamelin-Morrissette - J. Girouard - C. Vaillancourt - C. Reyes-Moreno


P169 IFN-G AND TNF-A SYNERGISE TO KILL INTESTINAL EPITHELIAL CELLS THROUGH A JAK1/2DEPENDENT PATHWAY / N. Saini* - P. Stamou - M. Bustamante-Garrido - P. Flood - S. Rajaram - J. A. Woznicki - P. Azablan - K. Nally
P170 INTERLEUKIN-6 AND INTERLEUKIN-11 CLASSIC, TRANS- AND CLUSTER SIGNALING BY SOLUBLE AND MEMBRANE-BOUND HYPER-CYTOKINES / L. Lamertz - J. Scheller*


P172 RE-VISITING THE MOLECULAR BASIS FOR TYPE I INTERFERON SIGNALING USING CRISPR KNOCKOUTS / G. Schreiber* - V. Urin - M. Shemesh

P173 THE ROLE OF TYPE I INTERFERON RECEPTORS IN MEDIATING DIFFERENTIAL ACTIVITY / M. Shemesh* - G. Schreiber

P174 CYTOKINES BOOST TRANSCRIPTIONAL OUTPUT IN NK CELLS VIA CHROMATIN REMODELING AND RAPID REDISTRIBUTION OF TRANSCRIPTION FACTOR BINDING / H.-Y. Shih* - G. Sciume’ - J. O’Shea

P176 SERINE 727 PHOSPHORYLATION OF STAT1 MODULATES A TYPE I INTERFERON DRIVEN NEURO-INFLAMMATORY DISEASE / P. Songkhunawej* - M. Hofer


P178 TUMOR NECROSIS FACTOR ALPHA AND INTERLEUKINS IL-1, IL-4, IL-6, IL-7, IL-8, IL-10, AND IL-12 WITH COMPLEX INFLAMMATORY, ANTI-INFLAMMATORY AND REGULATORY FUNCTIONS ARE CONTRIBUTING TO THE PATHOGENESIS OF COPD IN LUNG AIRWAYS / Z. Vitenberga* - M. Pilmane - A. Babjoniseva


P181 CHARACTERIZATION OF A SMALL PEPTIDE WITH UNKNOWN FUNCTION THAT IS LIKELY INVOLVED IN THE HOST INNATE AND ADAPTIVE IMMUNE RESPONSE / H. Young* - N. Tarasova - M. Sanford - W. Hu

P181.A DISSECTING IMMUNE CELL VARIABILITY IN CYTOKINE SIGNALLING BY SINGLE CELL MASS CYTOMETRY AND COMPUTATIONAL MODELLING / R. Mukherjee* - G. Altan-Bonnet

P181.B MODULATION OF TREG BY IL-2 AS A REVIVED THERAPEUTIC STRATEGY FOR AUTOIMMUNE DISEASES / L. Xu - X. Song - L. Su - Y. Zheng - J. Sun*

P181.C SIMULTANEOUS QUANTIFICATION OF INFLAMMATORY DISEASE BIOMARKERS USING COMMON LAB FLOW CYTOMETERS / P. Rughwani - B. Sun - J. Lehmann - S. Ji - W. Jiang*

Cytokines in allergy and Th2 immunity

P182 PYROPTOSIS IS A NOVEL MECHANISM OF IL-33 RELEASE FROM AIRWAY EPITHELIAL CELLS / O. Bernard* - M. Lachowicz-Scroggins - L. Sharp - E. Gordon


P185 TEMPORAL ABROGATION OF IL-4-SIGNALING IS DETERIMENTAL FOR AMELIORATION OF TH2 AND TH17 INFLAMMATION IN OVALBUMIN INDUCED ALLERGIC ASTHMA / J. Khumalo* - F. Kirstein - S. Hadebe - M. Scibiorek - F. Brombacher


P189  CHRONIC ETHION EXPOSURES AND ENDOTOXIN INTERACTION INDUCE PULMONARY DAMAGE AND GENOTOXICITY IN MICE / G. Verma* - C. S. Mukhopadhyay - R. Verma - B. Singh - R. S. Sethi

P189.A  A UNIQUE ROLE FOR B CELL IGM ISOTYPE IN ALLERGIC AIRWAY DISEASE / S. Hadebe* - J. Khumalo - M. Scibiorek - F. Kirstein - F. Brombacher


Cytokines in cancer development and antitumor immune therapy


P191  THE RXR AGONIST LG100268 ALTERS POLARIZATION OF BONE MARROW-DERIVED MACROPHAGES / N. Raychaudhuri* - K. Liby

P192  IL-6 TRANS-SIGNALING AND ADAM17 REQUIRED FOR EGF-R–INDUCED INTESTINAL TUMORS: NOVEL THERAPEUTIC PERSPECTIVES / S. Rose-John*


P195  DARK SIDE OF INTERFERON GAMMA SIGNALING IN TRIPLE NEGATIVE BREAST CANCER / S. Singh* - R. Chakrabarti

P196  NLRS ARE POTENTIAL BIOMARKERS FOR CARCINOGENESIS, AND ERS PARTICIPATE IN NLR-ASSOCIATED SIGNALING PATHWAYS BY DIRECTLY REGULATING NLRS / W. Fan - X. Gao - S. Song*

P197  BLYS ANTAGONIST DESIGNED BY CADD AMELIORATES COLLAGEN-INDUCED ARTHRITIS / W. Zhu - X. Sun - Z. Li - R. Li - J. Sun*

P198  PREDICTING CANCER SURVIVAL: IFN PRODUCTION VALUES DIFFER IN SHORT-TERM AND LONG-TERM CANCER SURVIVORS / K. Uno* - K. Yagi


P200  MURINE GUANYLATE-BINDING PROTEIN-2 (MGBP-2) INHIBITS TRIPLE-NEGATIVE BREAST CANCER MIGRATION IN VITRO / D. Vestal* - G. Nyabuto


P201.B  MIGRATION AND PROLIFERATION OF HEP3B CELLS IN 3D IN RESPONSE TO THE PRESENCE OF GROWTH FACTORS PRINTED ON A 384-PILLAR PLATE WITH SIDEWALLS / N. Janto* - A. Roth - M.-Y. Lee

P201.C  PREDICTING CANCER SURVIVAL: IFN PRODUCTION VALUES DIFFER IN SHORT-TERM AND LONG-TERM CANCER SURVIVORS / K. Uno* - K. Yagi

Cytokines in cancer development and antitumor immune therapy

P201.D  MURINE GUANYLATE-BINDING PROTEIN-2 (MGBP-2) INHIBITS TRIPLE-NEGATIVE BREAST CANCER MIGRATION IN VITRO / D. Vestal* - G. Nyabuto

P202  PREDICTING CANCER SURVIVAL: IFN PRODUCTION VALUES DIFFER IN SHORT-TERM AND LONG-TERM CANCER SURVIVORS / K. Uno* - K. Yagi


P204  MURINE GUANYLATE-BINDING PROTEIN-2 (MGBP-2) INHIBITS TRIPLE-NEGATIVE BREAST CANCER MIGRATION IN VITRO / D. Vestal* - G. Nyabuto

P205  PREDICTING CANCER SURVIVAL: IFN PRODUCTION VALUES DIFFER IN SHORT-TERM AND LONG-TERM CANCER SURVIVORS / K. Uno* - K. Yagi


P207  MURINE GUANYLATE-BINDING PROTEIN-2 (MGBP-2) INHIBITS TRIPLE-NEGATIVE BREAST CANCER MIGRATION IN VITRO / D. Vestal* - G. Nyabuto

P208  PREDICTING CANCER SURVIVAL: IFN PRODUCTION VALUES DIFFER IN SHORT-TERM AND LONG-TERM CANCER SURVIVORS / K. Uno* - K. Yagi


P210  MURINE GUANYLATE-BINDING PROTEIN-2 (MGBP-2) INHIBITS TRIPLE-NEGATIVE BREAST CANCER MIGRATION IN VITRO / D. Vestal* - G. Nyabuto

P211  PREDICTING CANCER SURVIVAL: IFN PRODUCTION VALUES DIFFER IN SHORT-TERM AND LONG-TERM CANCER SURVIVORS / K. Uno* - K. Yagi


P213  MURINE GUANYLATE-BINDING PROTEIN-2 (MGBP-2) INHIBITS TRIPLE-NEGATIVE BREAST CANCER MIGRATION IN VITRO / D. Vestal* - G. Nyabuto

P214  PREDICTING CANCER SURVIVAL: IFN PRODUCTION VALUES DIFFER IN SHORT-TERM AND LONG-TERM CANCER SURVIVORS / K. Uno* - K. Yagi


P216  MURINE GUANYLATE-BINDING PROTEIN-2 (MGBP-2) INHIBITS TRIPLE-NEGATIVE BREAST CANCER MIGRATION IN VITRO / D. Vestal* - G. Nyabuto

P217  PREDICTING CANCER SURVIVAL: IFN PRODUCTION VALUES DIFFER IN SHORT-TERM AND LONG-TERM CANCER SURVIVORS / K. Uno* - K. Yagi


P219  MURINE GUANYLATE-BINDING PROTEIN-2 (MGBP-2) INHIBITS TRIPLE-NEGATIVE BREAST CANCER MIGRATION IN VITRO / D. Vestal* - G. Nyabuto

P220  PREDICTING CANCER SURVIVAL: IFN PRODUCTION VALUES DIFFER IN SHORT-TERM AND LONG-TERM CANCER SURVIVORS / K. Uno* - K. Yagi
Cytokines in skin inflammatory diseases

P202 IL-17A IS ANTI-FIBROTIC IN SYSTEMIC SCLEROSIS SKIN WHERE IT MAY SYNERGIZE OR ANTAGONISE TGF-B / A. M. Dufour* - M. Alvarez - S. Lemeille - M. E. Truchetet - N. C. Brembilla - C. Chizzolini

P203 IL-23 ACTIVATION OF MDL-1+ CELLS IS CRITICAL IN THE PATHOGENESIS OF PSORIATIC ARTHRITIS / C. Nguyen* - D. Hui - I. Adamopoulos

P204 PROSTAGLANDIN E2 AMPLIFIES IL-17 SECRETION BY GAMMA DELTA T CELLS / B. Polese* - C. Leung Soo - H. Zhang - G. Fontes - I. King

P205 PHENOTYPIC AND FUNCTIONAL CHARACTERIZATION OF AUTOACTIVE RESIDENT AND RECIRCULATING MEMORY T CELLS IN VITILIGO REVEALS LOCAL IFNG AND CHEMOKINE PRODUCTION IN SKIN ARE USED TO COORDINATE AUTOIMMUNITY / J. M. Richmond* - M. Rashighi - P. Agarwal - J. P. Strassner - M. Garg - K. I. Essien - L. S. Pell - J. E. Harris


P207 ZEARALENONE (ZEA) CAN RELIEVE DEXTRAN SULPHATE SODIUM (DSS)-INDUCED INFLAMMATORY REACTION / C. Ding - S. Song*


P207.B TYPE I INTERFERONS MODULATE ULTRAVIOLET RADIATION INDUCED SUPPRESSION OF IMMUNE RESPONSES / N. Yusuf* - M. A. Sherwani - I. Ahmad - C. Raman

Innate immunity


P211 A FUNCTIONAL ROLE FOR CELLULAR HETEROGENEITY IN THE TYPE I INTERFERON RESPONSE TO VIRAL INFECTION / S. Leviyang* - I. Griva

P212 INTERFERON SUPPRESSION BY FIBROBLAST GROWTH FACTOR 2 ENHANCES ZIKA VIRUS INFECTION OF HUMAN FETAL BRAIN CELLS / D. Limonta* - J. Jovel - A. Kumar - J. Lu - W. Branton - C. Power - T. C. Hobman

P213 REGULATION OF INNATE IMMUNE RESPONSES AND VIRUS REPLICATION BY PACT / P. Luthra* - C. F. Basler

P214 IFN-BETA INDUCED EPIGENETIC MEMORY IN HUMAN BRONCHIAL EPITHELIAL CELLS / S. V. Mayer* - E. R. Winkelmann - B. B. Leitao - S. Shapira

P215 CHARACTERIZATION OF THE GLOBAL CELLULAR TRANSCRIPTOMICS OF TYPE I IFN RESPONSE IN GUINEA PIGS AND INHIBITORY EFFECTS OF KEY GUINEA PIG ISGS TO CYTOMEGALOVIRUS / A. McGregor* - M. Markert - K. Y. Choi


P217 ARID5A EXPRESSION IS INDUCED THROUGH MYD88-DEPENDENT PATHWAY IN RESPONSE TO TLR4 STIMULATION IN IFN-GAMMA-SENSITIZED HUMAN MACROPHAGES / H. Metwally* - T. Kishimoto

P218 N-TERMINAL CYSTEINES OF NLRP3 DETERMINE AGONIST SPECIFICITY / A. Nagar* - T. Rahman - J. A. Harton
P219 REACTIVE OXYGEN SPECIES REGULATE CALCINEURIN-TFEB PATHWAY DURING BACTERIAL PHAGOCYTOSIS / M. Najibi* - J. Irazoqui


P222 DEVELOPMENT OF A HOMOGENEOUS, BIOLUMINESCENT IMMUNOASSAY FOR RELEASED IL-1 BETAB / M. O’Brien* - J. Cali - D. Lazar


P224 EBOLAVIRUS GLYCOPROTEIN-MEDIATED INFLAMMATORY RESPONSES / J. Olejnik* - D. Cantoni - J. S. Rossman - E. Muhlberger


P227 GEF-H1 REGULATES TYPE I AND TYPE III INTERFERON EXPRESSIONS FOR ANTIVIRAL HOST DEFENSES IN THE INTESTINE / Y.-C. Peng* - Y.-C. Chen - H.-S. Chiang


P229 TYPE I INTERFERON IS IMPORTANT FOR ACINETOBACTER BAUMANNII RESOLUTION IN A PNEUMONIA MODEL / S. Pires* - D. Parker

P230 INFLAMMASOME-INDEPENDENT ACTIVATION OF IL-1B IN THE LUNG IN RESPONSE TO TAPHYLOCOCCUS AUREUS INFECTION / S. Pires* - D. Parker

P231 IFITS, A FAMILY OF INTERFERON STIMULATED GENES, ALLEVIATE EXPERIMENTAL ACUTE COLITIS / D. Poddar* - G. Sen

P232 INNATE IMMUNE SIGNALING DRIVES PATHOGENIC EVENTS LEADING TO AUTOIMMUNE DIABETES / N. Qaisar* - B. Satish - A. Kucukural - R. Racicot - G. Ryan - M. Garber - J. Mordes - J. Wang

P233 EVOLUTIONARY CONSERVATION OF ISG15’S ABILITY TO NEGATIVELY REGULATE IFN SIGNALING / X. Qiu* - D. Bogunovic

P234 IL-17B USES IL-17RA AND IL-17RB TO INDUCE TYPE-2 INFLAMMATION FROM HUMAN IMMUNE CELLS / V. Ramirez-Carrozzi* - R. Pappu


P236 VIRAL SUPPRESSORS OF IFN RESPONSES: PARAMYXOVIRUS V PROTEIN / L. Sanchez-Aparicio* - L. J. Feinman - M. L. Shaw - A. Garcia-Sastre


P239  FUNCTIONAL ANALYSIS OF IRF9 POST-TRANSLATIONAL MODIFICATIONS / K. S. Schulz* - K. L. Mossman


P242  SCREENING AND IDENTIFICATION OF BINDING DOMAIN OF RHDV VP60 TO HISTOBLOOD GROUP ANTIGENS / Y. Song* - Y. Zuo - F. Wang - B. Hu - Z. Fan - M. Chen


P244  IN VIVO IDENTIFICATION OF CELL TYPE-DEPENDENT DISTINCT AND REDUNDANT FUNCTIONS OF INTERFERONS IN PROTECTION AGAINST INFLUENZA / S. Stifter* - A. Sawyer - N. Bhattacharyya - W. J. Britton - A. Sher - C. G. Peng

P245  AGE-RELATED LOSS OF MIGRATORY DENDRITIC CELLS IMPAIRS THE EARLY INNATE ANTIVIRAL RESPONSE / C. Stotesbury* - E. Wong - L. Sigal


P249  INHIBITION OF DENDRITIC CELLS IL-12 PRODUCTION BY PARACOCCIDIOIDES BRASILIENSIS / A. H. Tavares* - G. S. Silva - D. Silva


P251  REGULATION OF THE INTERFERON RESPONSE BY CIS AND TRANS-ACTING LONG NON-CODING RNAs / S. Valadkhan* - L. Plasek


P253  TL9-SIGNALING REQUIRE LIGAND-INDUCED PHOSPHORYLATION OF TWO SPECIFIC TYROSINE RESIDUES BY EGFR AND SYK / M. M. Veleeparambil* - D. Poddar - G. C. Sen

P254  CHARACTERIZATION OF IFNE AND IFNK RECEPTOR BINDING AND NEUTRALIZATION BY THE POXVIRUS ANTAGONIST B18R / B. Harris - J. Schreiter - M. Chevrier - J. Jordan - M. R. Walter


P257  EVOLUTIONARY CONSERVED FLAVIN-CONTAINING MONOOXYGENASE FUNCTIONS IN HOST DEFENSE IN C. ELEGANS / K. Wani* - S. Taubert - J. E. Irazoqui

P259  THE ROLE OF INTERLEUKIN-10 IN REGULATING NEUROINFLAMMATION RELEVANT TO TAUOPATHIES / L. Weston* - S. Jiang - D. Chisholm - K. Bhaskar

P260  SANDFLY FEVER SICILIAN VIRUS NSS DIRECTLY TARGETS PROMOTER-BINDING OF IRF3 TO INHIBIT TYPE I INTERFERON INDUCTION / J. D. Wuerth* - M. Habjan - A. Pichlmair - G. Superti-Furga - F. Weber


P262  SYSTEMIC MATERNAL ANTI-VIRAL RESPONSES LEAD TO ABNORMAL FETAL NEURAL TUBE DEVELOPMENT / L. Yockey* - D. Musaev - C. Qi - N. Sestan - A. Pyle - A. Iwasaki

P263  PATHOGEN-ASSOCIATED MOLECULAR PATTERNS INDUCED ADP FACILITATES MONOCYTE RECRUITMENT THROUGH CCL-2 PRODUCTION IN BACTERIAL INFECTION / X. Zhang* - M. Qian


P265.A  TARGETING STING WITH COVALENT SMALL-MOLECULE INHIBITORS / A. Ablasser*


P265.D  KINETICS OF DOWNREGULATION OF TRANSCRIPTION FACTOR E2-2 BY TLR7, TLR9, AND TLR4 AGONISTS IN PRIMARY HUMAN PLASMACYTOID DENDRITIC CELLS / H. Dewald* - P. Fitzgerald-Bocarsly


P265.F  THE HUMAN CAP METHYLTRANSFERASE 1 CMTR1 REGULATES THE EXPRESSION OF CERTAIN INTERFERON STIMULATED GENES / D. Snider* - G. Williams - N. Gokhale - S. Horner

P265.G  TYPE I IFNS DRIVE HEMATOPOIETIC PROGENITOR CELL LOSS VIA RIPK3-DEPENDENT IL-18 PRODUCTION AND RIPK1-DEPENDENT CELL DEATH / K. C. Macnamara* - J. Smith - J. Howard


Mucosal immunity

P266  VIRAL INFECTION DRIVES PLASTICITY IN COMMENSAL-INDUCED GAMMA DELTA T CELLS AT THE OCULAR SURFACE / D. M. Previte* - B. R. Treat - A. J. St. Leger


P269  MULTI-TARGETING STRATEGIES AGAINST INFLAMMATORY DISEASES / U. Saqib*

P270  PYRIN INFLAMMASOME REGULATES MUCOSAL IMMUNITY THROUGH DISTINCT MECHANISMS / D. Sharma* - A. Malik - C. Guy - P. Vogel - T.-D. Kanneganti

P271  LONG NON-CODING RNAs (lncRNAs) AS REGULATORS OF INTESTINAL HOMEOSTASIS AND INFLAMMATION / L. Shmuel Galia* - F. Humphries - K. A. Fitzgerald

P273 SUPPRESSION OF IL-17F, BUT NOT OF IL-17A, PROVIDES PROTECTION AGAINST COLITIS BY INDUCING TREG CELLS THROUGH MODIFICATION OF THE INTESTINAL MICROBIOTA / C. Tang* - Y. Iwakura

P274 VERSATILE EFFECTS OF IL-6 ON NITRIC OXIDE PRODUCTION DURING ULCERATIVE COLITIS / R. Toumi* - I. Soufi - H. Rafa - C. Touil


P276 SYSTEMIC IL-18 AND INTESTINAL MHC-II ARE REGULATED DISTINCTLY BY MICROBIAL DYSBIOSIS AND INFLAMMASOME ACTIVATION / L. Van Der Kraak* - C. Schneider - P. Tsoukas - S. W. Canna

P277 NEW LESSONS IN ANTIFUNGAL IMMUNITY: THE ORAL EPITHELIUM EXPLOITS A FUNGAL VIRULENCE FACTOR TO DRIVE INNATE IL-17 RESPONSES DURING INFECTION / A. Verma* - J. Richardson - D. Moyes - B. Hube - J. Naglik - S. Gaffen


P279.A ROLE OF A NOVEL TRANSPORTER SLC46A3 IN MAINTENANCE OF INTESTINAL INTEGRITY AND MICROFLORA / A. Nandy* - K. Okuda - N. Silverman


T cell differentiation and function

P280 AN IN VITRO MODEL OF CD8+ MEMORY AND EFFECTOR T CELL FATE BASED ON DIFFERENTIAL PRODUCTION OF INTERFERON-GAMMA / M. Balood - J. Baillargeon - S. Talbot - M. Rangachari*


P284 IL-10-TRANSFECTED DENDRITIC CELLS STIMULATE IL-10-DEPENDENT TOLERANCE IN C57BL6 MICE IN VIVO / J. Khantakova - V. Tereschenko* - A. Silkov - A. Maksyutov - S. Sennikov


P286 THE INSUFFICIENCY OF METABOLIC HORMONE LEPTIN IMPAIRS T THE FUNCTION OF TFH CELLS AND CONFFS A RISK OF POOR VACCINE RESPONSES / D. Yu* - J. Deng - L. Lu
AWARD WINNERS

**Seymour & Vivian Milstein Award for Excellence in Interferon and Cytokine Research**

**Luke O’Neill** (Trinity College Dublin, Ireland)
Presentation on Saturday, 27 October, 17:15 – 17:50 in Opening Ceremony

**Thirumala Kanneganti** (St. Jude’s, Memphis, USA)
Presentation on Saturday, 27 October, 17:50 – 18:25 in Opening Ceremony

**ICIS Honorary Lifetime Membership Awardee:**

**Robert Fleischmann** (Central Michigan University College of Medicine, USA)

**ICIS BioLegend William E. Paul Awardee:**

**Giorgio Trinchieri** (NCI, NIH, USA)
Presentation on Tuesday, 30 October 15:55 - 16:25 in Plenary 3

**ICIS Distinguished Service Awardee:**

**Tadamitsu Kishimoto** (Osaka University, Japan)

**Milstein Young Investigator Awardees:**

**Cristina Bergamaschi** (National Cancer Institute at Frederick, Frederick, USA)
TREATMENT WITH HETERODIMERIC IL-15 SHAPES THE CYTOKINE AND CHEMOKINE MILIEU OF THE TUMOR, PROMOTING TUMOR INFILTRATION BY CYTOTOXIC LYMPHOCYTES: A GENERAL METHOD FOR LYMPHOCYTE ENTRY IN TUMORS
Presentation on Sunday, 28 October, 09:45 – 10:00 in Plenary Session I

**Ricardo Rajsbaum** (University of Texas Medical Branch, Galveston, USA)
REGULATION OF NOVEL PATTERN RECOGNITION RECEPTOR SIGNALING AND IFN INDUCTION BY UNANCHORED K48-LINKED POLYUBIQUITIN CHAINS
Presentation on Sunday, 28 October, 10:00-10:15 in Plenary Session I

**Vijay Rathinam** (UConn Health School of Medicine, Farmington, USA)
THE EXPANDING FUNCTIONS OF THE INFLAMMASOME COMPLEXES
Presentation on Tuesday, 30 October, 11:00 – 11:25 in Symposium 15: Inflammasome and IL1 Family members II

**Gregory F. Sonnenberg** (Weil Cornell, New York City, USA)
CYTOKINE REGULATION OF INTESTINAL HEALTH
Presentation on Sunday, 28 October, 16:30 – 16:55 in Symposium 6: Intestinal Homeostasis

**Munir Akkaya** (NIAID, NIH, Bethesda, MD, USA)
TYPE I INTERFERONS REGULATE B CELL DEVELOPMENT AND DIFFERENTIATION
Presentation on Monday, 29 October, 10:20-10:35 in Plenary 2: Advances in Pathogenic Th17 axis of evil

**Christina Fleischmann Awardee:**

**Sophia Davidson** (Walter and Eliza Hall Institute for Medical Research, Parkville, Australia)
DELINEATION OF THE INFLAMMATORY PATHWAY BEHIND PROTEASOME-ASSOCIATED AUTOINFLAMMATORY SYNDROME
Presentation on Sunday, 28 October, 10:15 – 10:30 in Plenary Session I

**Sidney & Joan Pestka Graduate Awardee:**

**Erika Engelowski** (Heinrich-Heine-University, Duesseldorf, Germany)
DI- AND TRIMERIC BIOLOGICAL SWITCHES MADE OF NANOBODY-CYTOKINE RECEPTOR FUSION PROTEINS SIMULATE NATURAL SIGNAL TRANSDUCTION
Presentation on Sunday 28 October, 12:15-12:25 in Symposium 1: Innate Sensing and Signaling

**Sidney & Joan Pestka Post Graduate Awardee:**

**Christoph Schneider** (University of California, San Francisco, San Francisco, USA)
A METABOLITE-TRIGGERED TUFT CELL-ILC2 CIRCUIT DRIVES SMALL INTESTINAL REMODELING
Presentation on Sunday 28 October, 12:25-12:35 in Symposium 1: Innate Sensing and Signaling
MILSTEIN TRAVEL AWARD WINNERS

Sabrin Albeituni - USA
Nilesh Amatya - USA
Marina Babic Cac - Germany
Heekyong Bae - USA
Amrita Bhattacharjee - USA
Susan Carpenter - USA
Saurabh Chattopadhyay - USA
Ya-Shan Chen - Taiwan
Hyeon Joo Cheon - USA
Christina Cho - USA
Min-Kyung Choo - USA
Dominic De Nardo - Australia
Pratik Deb - USA
Alicia Derrac Soria - United Kingdom
Virginie Deswaerte - Australia
Senad Divanovic - USA
Xingrong Du - USA
Adriana Forero - USA
Ka Yee Fung - Australia
Arunakumar Gangapalara - USA
Christoph Garbers - Germany
Laura Garcia Perez - Germany
Christopher Garris - USA
Eirini Giannoudaki - Ireland
Claire Gorby - United Kingdom
Aleks Guanizo - Australia
Tzachi Hagai - United Kingdom
Daniel Harari - Israel
David Hare - Canada
Emily Hemann - USA
Dulcemaria Hernandez - USA
Kiyoshi Hirahara - Japan
Harry Hurley - USA
Mihyun Hwang - USA
Motohiko Kadoki - USA
Dhan Kalvakolanu - USA
Apurva Kanneganti - USA
Richa Kapoor - USA
Rajendra Karki - USA
Ryoji Kawakami - Japan
Alison Kell - USA
Myoungjoo Kim - USA
Taehwan Kim - Korea
Kate Lawlor - Australia
Ming-Chin Lee - Australia
Helene Liu - Taiwan
Nicola Lore' - Italy
Jaodi Luo - USA
Raymond Luong - Australia
Priya Luthra - USA
Saikat Majumder - USA
Elizabeth Mann - United Kingdom
Ashley Mansell - Australia
Constance McElrath - USA
Aya Nambu - USA
Sukumar Namineni - Germany
Olusegun Onabajo - USA
Jose Ordovas-Montanes - USA
Jeongho Park - USA
Genevieve Pepin - Australia
Leah Plasek - USA
Sree Pulugulla - USA
Xueer Qiu - USA
Orna Rabinovich - USA
Stefan Rose-John - Germany
Maria Sanchez-Aparicio - USA
Kimberly Schluns - USA
Johannes Schwerk - USA
Deepika Sharma - USA
Om Prakash Singh - India
Saahlata Singh - USA
Pattama Songkhunawej - Australia
Sebastian Stifter - Australia
Colby Stotesbury - USA
Sarah Straub - Australia
Odsuren Sukhbaatar - Japan
Jian Sun - China
Hock Tay - Australia
Javier Uceda - United Kingdom
Julio Valencia - USA
Sharat Vayttaden - USA
Manoj Veleeparambil - USA
Ran Wang - Australia
Jerzy Woznicki - Ireland
Keiko Yasuda - Japan
Liang Ye - Germany
Chienhsiung Yu - Australia
Di Yu - Australia
COMPANY PROFILES

Abbvie

Abcam plc
@: catherine.tarrade@abcam.com
W: www.abcam.com
T: +441223696000

As an innovator in reagents and tools, Abcam’s purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways. Already a pioneer in data sharing and ecommerce in the life sciences, Abcam’s ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health.
To find out more, please visit www.abcam.com.

Amgen, Inc.
W: www.amgen.com
T: +8054471000

Amgen is one of the world’s leading biotechnology companies. Amgen is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses.

AYOXXA Biosystems Inc.
@: info@ayoxxa.com
W: www.ayoxxa.com
T: +492212225290

AYOXXA Biosystems is an international life science tools company based in Cologne (Germany) with an office in Boston, MA.
LUNARIS™ is AYOXXA’s beads-on-a-chip multiplexing platform. The Company offers LUNARIS™ Kits and testing services for advanced biomarker quantification. The inflammation cluster of kits target selections of soluble Cytokines implicated in T cell differentiation and effector functions. They can inform a range of medical questions including allergies, autoimmunity, ophthalmology, immuno-oncology, and beyond.

BD Biosciences
@: anne.messing@bd.com
W: www.bdbiosciences.com
T: 4084329475

BD Biosciences, a division of BD, provides flow cytometers, reagents, tools and services to support researchers and clinicians who study disease and seek to improve care. With more than 40 years of experience and innovation in flow cytometry, BD continues to aid researchers in advancing the world of health.

Biogen
@: Public.affairs@biogen.com
W: https://www.biogen.com
T: +17814642000

At Biogen, our mission is clear: We are pioneers in neuroscience. Since our founding in 1978 as one of the world’s first global biotechnology companies by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases.
Our focus on neuroscience, our deep scientific expertise, and our courage to take risks make us leaders in the research and development of medicines to transform neuroscience to benefit society. We care deeply, work fearlessly, and are humbled by the opportunity to change lives.
BioLegend
@: info@biolegend.com
W: www.biolegend.com
T: 8772465343

BioLegend develops and manufactures highly recognized, world-class antibodies, recombinant proteins, and reagents. We provide the highest quality products at an outstanding value, with superior customer support. Our portfolio includes tools for immunology, neuroscience, cell biology, and cancer research. We have developed over 18,000 products, cited in over 27,000 peer-reviewed publications. BioLegend in San Diego, California operates under an ISO 13485:2003 certified quality management system.

Bio-Techne
W: www.bio-techne.com
T: +16123792956

Bio-Techne brings together the prestigious life science research brands of R&D Systems, Novus Biologicals, Tocris Bioscience, ProteinSimple, and Advanced Cell Diagnostics to provide researchers with high-quality reagents and instruments. We specialize in high quality antibodies, proteins, immunoassays, small molecules, RNA probes, and instruments for protein and genomic characterization.

Boehringer Ingelheim
W: www.boehringer-ingelheim.com

Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies. Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry's top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals.

Bon Opus Biosciences
@: yufang.shao@bonopusbio.com
W: www.bonopusbio.com
T: 8009436396

Recombinant Cytokine, antibody, ELISA supplier and custom protein, antibody and peptide production service.

Bristol-Myers Squibb

This activity was supported by an educational grant from Celgene Corporation

Celgene

This activity was supported by an educational grant from Celgene Corporation

Cytokine (Elsevier)
@: d.korporaal@elsevier.com
W: https://www.journals.elsevier.com/cytokine

Cytokine, the official journal of the International Cytokine & Interferon Society, is devoted to the study of molecular biology, genetics, biochemistry, immunology, and genome-wide association studies, pathobiology, diagnostic and clinical applications of all known interleukins, hematopoietic factors, growth factors, cytotoxins, interferons, new cytokines, and chemokines.

RELX Group is a global provider of information & analytics for professional and business customers across industries. In short, we enable our customers to make better decisions, get better results and be more productive.

Eli Lilly

This activity was supported by an educational grant from Lilly.
For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
Five Prime Therapeutics

@: pr@fiveprime.com  
W: www.fiveprime.com  
T: +14153565600

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime’s comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and the focus of the company’s R&D activities. Five Prime has promising product candidates in clinical and late preclinical development. For more information, please visit www.fiveprime.com or follow us on LinkedIn, Twitter and Facebook.

GSK

Genentech, Inc.

Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 40 years. Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. We are among the world’s leading biotech companies, with multiple products on the market and a promising development pipeline.

Janssen Immunology

@: ImmunologyTA@its.jnj.com  
W: https://www.janssen.com/immunology  
T: 12156285000

Janssen Immunology is a place where passion meets purpose. Our ultimate vision is a world free from immune diseases and we recognize that, to achieve this, we will translate internal and external science to deliver therapies that treat, prevent, intercept and cure immune-mediated diseases.

For more than 20 years, we have been working tirelessly to change the treatment paradigm for patients and their families. We look forward to continuing our leadership and innovation in optimizing and tailoring therapeutic advances to develop unique treatment options for individual patients in every part of the world.

Kenneth Rainin Foundation

@: info@krfoundation.org  
W: http://krfoundation.org  
T: +15106255200

At the Rainin Foundation, we support novel, high-risk research and challenge investigators to push boundaries. The beginning of an idea is particularly exciting because it’s where we can make the greatest impact. Our unique funding approach to Inflammatory Bowel Disease (IBD) research could lead to new, transformative discoveries for IBD and other chronic diseases. Our investments enable researchers to test ideas and gather data to advance the understanding of IBD. Beyond funding, we recognize the importance of dialogue and facilitate collaboration among innovative researchers to enhance discoveries.

Mary Ann Liebert, Inc

W: www.liebertpub.com/jir

The Journal of Interferon & Cytokine Research (www.liebertpub.com/jir) provides authoritative peer-reviewed research, analysis, and advances on the therapeutic role of cytokines and IFNs. The Journal, now in its 38th year, delivers current findings on emerging topics in this niche community, including the role of IFNs in the therapy of diseases such as multiple sclerosis, the understanding of the third class of IFNs, and the identification and function of IFN-inducible genes. An official journal of the International Cytokine & Interferon Society.
MedImmune
@: humblesa@medimmune.com
W: www.medimmune.com
T: +13013980000

MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across Oncology, Respiratory, Cardiovascular, Renal and Metabolic Diseases, and Infection and Vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centres, with additional sites in Cambridge, UK and South San Francisco, CA.

Merck & Co., Inc.
W: www.merck.com

For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.

Meso Scale Discovery
@: marketing@meso-scale.com
W: www.mesoscale.com
T: 12403142600

Meso Scale Discovery (MSD®) is a leader in high performance, multiplex-enabled biomarker assays for cytokines, toxicology, neurodegeneration and metabolic disease research, used by leading biopharmaceutical and academic researchers in human and animal model studies. MSD’s proprietary electrochemiluminescence (ECL) platform delivers exceptional sensitivity, wide dynamic range and rapid turnaround.

MilliporeSigma
@: NACustomerservice@emdmillipore.com
W: www.milliporesigma.com
T: 8666455439

MilliporeSigma is the life science business of Merck KGaA, Darmstadt, Germany. Our broad offering of 300,000 products includes the Millipore® portfolio of preparation, separation, filtration and testing products and technologies – strongly rooted in quality, reliability, time-tested processes and regulatory expertise. Our experience and application knowledge is relied on worldwide.

Mucosal Immunology Studies Team (MIST)

The Mucosal Immunology Studies Team (MIST) comprises the grant recipients of the NIAID’s Mucosal Immunology Studies Group Initiative, RFA-AI-15-023. The goal of MIST is to discover and define novel basic immune mechanisms, cells, mediators, and pathways that provide a more sophisticated understanding of mucosal immune defense mechanisms; to explore innovative hypotheses; and to address difficult unsolved questions in mucosal immunity. The ultimate goal is to develop the knowledge base needed to facilitate future development of vaccines and immunotherapies to protect mucosal surfaces from infection and immune-mediated pathology.
Our mission is to discover new ways to improve and extend people’s lives. Our vision is to be a trusted leader in changing the practice of medicine. We use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.

PBL Assay Science

PBL is proud to be a part of the Cytokines 2018 meeting. We provide cytokine assay solutions that include proteins antibodies, single-analyte assay kits, cytokine multiplex kits and assay services to researchers around the world. Whether researches are done in Human, Mouse or non-human primate models, scientists have come to rely on PBL’s assay solutions for results they can trust. From accurate detection of human IFN-beta in autoimmune diseases to sub-picogram cytokine measurement assays, our offers are designed to provide you with high quality experimental data. Visit us at booth 4/5 to discover how we can assist you in your research project.

PeproTech, Inc.

PeproTech creates the building blocks of your life science research by manufacturing high-quality products that advance scientific discovery and human health. Since 1988, PeproTech has grown into a global enterprise manufacturing an extensive line of Recombinant Human, Murine and Rat Cytokines, Animal-Free Recombinant Cytokines, Monoclonal Antibodies, Affinity Purified Polyclonal Antibodies, Affinity Purified Biotinylated Polyclonal Antibodies, ELISA Development Kits, Cell Culture Media Products and GMP Cytokines.

Pfizer

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube, and like us on Facebook at Facebook.com/Pfizer.

Regeneron

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our ability to translate science into medicine has led to seven FDA-approved treatments and numerous product candidates, all homegrown in our labs. Our medicines and pipeline help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases and more. Regeneron is accelerating and improving the drug development process through our proprietary VelociSuite® technologies and research initiatives like the Regeneron Genetics Center.
Journal of Experimental Medicine publishes papers providing novel conceptual insight into immunology, neuroscience, cancer biology, vascular biology, microbial pathogenesis, and stem cell biology. JEM is published by Rockefeller University Press, a department of The Rockefeller University, a leading biomedical research university dedicated to conducting innovative, high-quality research to improve the understanding of life for the benefit of humanity. At JEM, all editorial decisions on research manuscripts are made through collaborative consultation between professional scientific editors and academic editorial board.

Sanofi
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi, Empowering Life

Science Immunology / AAAS
Science Immunology publishes original, peer-reviewed, science-based research articles that report critical advances in all areas of immunological research, including important new tools and techniques. Areas covered range from basic studies into the biology of innate and adaptive immunity to immune contributions to health and disease.

Society for Leukocyte Biology / Journal of Leukocyte Biology
The Society for Leukocyte Biology and their Journal (Journal of Leukocyte Biology) work to promote the discipline and support our membership through presentation and publication opportunities. With a vast award program supporting member travel to SLB and other meetings, numerous networking opportunities, and leadership roles for members at all career levels, SLB offers a unique and diverse community. Serving like-minded researchers and clinicians focused on the field of immunology and all its implications, applications, and practices, SLB welcomes all attendees to learn more about the benefits and community resources our society offers (www.leukocytebiology.org).

Surface Oncology
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD47, CD73, CD39 and IL-27. Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. The company has a pipeline of seven novel immunotherapies and a strategic collaboration with Novartis focused on up to three next-generation cancer immunotherapies.

Takeda
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. Innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in emerging markets, are currently fueling the growth of Takeda. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries.
MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across Oncology, Respiratory, Cardiovascular & Metabolic Diseases, and Infection and Vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centres, with additional sites in Cambridge, UK and South San Francisco, CA.

For more information, please visit www.medimmune.com
LAYOUT OF VENUE & EXHIBITION AREA
ACKNOWLEDGEMENTS

The Cytokines 2018 Organizing Committee wishes to express its gratitude to the following industry partners for their support of the meeting:

Platinum sponsors

Gold sponsors

Silver sponsor

Sponsors & Exhibitors

This activity was supported by an educational grant from Lilly.
For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
This activity was supported by an educational grant from Celgene Corporation
This activity was supported by a grant from Genentech
Funding for this conference was made possible [in part] by R13AI140628 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services, nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
Research reported in this publication was supported by the National Institute Of Allergy And Infectious Diseases of the National Institutes of Health under Award Number R13AI140628. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
THE DIFFERENCE OF

BRILLIANT TOOLS

AND BRILLIANTLY BRIGHT POLYMER DYES. Whether your aim is to minimize compensation or add new markers to complex experiments, BD’s brilliant dyes and custom reagent offerings can help simplify the world of flow cytometry. From our BD Horizon Brilliant™ dyes and BD OptiBuild™ custom reagents, to our new BD Horizon™ Guided Panel Solution (GPS), our offerings can help simplify difficult and time-consuming processes. And, if you require help and support, all our products/tools are backed by BD training, educational seminars and technical application support.

Discover more by visiting bdbiosciences.com/go/brilliant

bdbiosciences.com

BD Life Sciences, San Jose, CA, 95131, USA
Everything that makes us unique makes us uniquely good at the work we do together.

WE ARE THE MANY DARING, DIFFERENT PEOPLE OF PFIZER

ALL DRIVEN TO DISCOVER THE CURE.

Come and discover what we are all about at

pfizer.com/diversity